The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
This evidence‐ and consensus‐based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016. It is a joint initiative of the Dermatology Section of...
Gespeichert in:
| Veröffentlicht in: | Allergy (Copenhagen) Jg. 73; H. 7; S. 1393 - 1414 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Denmark
Blackwell Publishing Ltd
01.07.2018
|
| Schlagworte: | |
| ISSN: | 0105-4538, 1398-9995, 1398-9995 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | This evidence‐ and consensus‐based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU‐founded network of excellence, the Global Allergy and Asthma European Network (GA²LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) with the participation of 48 delegates of 42 national and international societies. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell‐driven disease, presenting with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria are disabling, impair quality of life and affect performance at work and school. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. In addition, it outlines evidence‐based diagnostic and therapeutic approaches for the different subtypes of urticaria. |
|---|---|
| AbstractList | This evidence‐ and consensus‐based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU‐founded network of excellence, the Global Allergy and Asthma European Network (GA²LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) with the participation of 48 delegates of 42 national and international societies. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell‐driven disease, presenting with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria are disabling, impair quality of life and affect performance at work and school. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. In addition, it outlines evidence‐based diagnostic and therapeutic approaches for the different subtypes of urticaria. This evidence- and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU-founded network of excellence, the Global Allergy and Asthma European Network (GA²LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) with the participation of 48 delegates of 42 national and international societies. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria are disabling, impair quality of life and affect performance at work and school. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. In addition, it outlines evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.This evidence- and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU-founded network of excellence, the Global Allergy and Asthma European Network (GA²LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) with the participation of 48 delegates of 42 national and international societies. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria are disabling, impair quality of life and affect performance at work and school. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. In addition, it outlines evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria. This evidence‐ and consensus‐based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU‐founded network of excellence, the Global Allergy and Asthma European Network (GA²LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) with the participation of 48 delegates of 42 national and international societies. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell‐driven disease, presenting with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria are disabling, impair quality of life and affect performance at work and school. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. In addition, it outlines evidence‐based diagnostic and therapeutic approaches for the different subtypes of urticaria. This evidence‐ and consensus‐based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation ( GRADE ) working group. The conference was held on 1 December 2016. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology ( EAACI ), the EU ‐founded network of excellence, the Global Allergy and Asthma European Network ( GA ² LEN ), the European Dermatology Forum ( EDF ) and the World Allergy Organization ( WAO ) with the participation of 48 delegates of 42 national and international societies. This guideline was acknowledged and accepted by the European Union of Medical Specialists ( UEMS ). Urticaria is a frequent, mast cell‐driven disease, presenting with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria are disabling, impair quality of life and affect performance at work and school. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. In addition, it outlines evidence‐based diagnostic and therapeutic approaches for the different subtypes of urticaria. |
| Author | Canonica, G. W. Church, M. K. Godse, K. Ensina, L. F. Baker, D. Kocatürk, E. Ballmer‐Weber, B. Danilycheva, I. V. Toubi, E. Maurer, M. Kaplan, A. Saini, S. S. Vena, G. A. Abdul Latiff, A. H. Bindslev‐Jensen, C. Staubach, P. Gonçalo, M. Nettis, E. Grattan, C. Brzoza, Z. Larenas‐Linnemann, D. Sussman, G. Zuberbier, T. Magerl, M. Craig, T. Sánchez‐Borges, M. Bernstein, J. A. Vestergaard, C. Wedi, B. Giménez‐Arnau, A. Hebert, J. Dressler, C. Schmid‐Grendelmeier, P. Hide, M. Rosumeck, S. Kapp, A. Oude‐Elberink, H. Kulthanan, K. Zhao, Z. Katelaris, C. H. Aberer, W. Leslie, T. A. Meshkova, R. Y. Buense Bedrikow, R. Asero, R. Werner, R. N. Nast, A. Metz, M. Mathelier‐Fusade, P. |
| Author_xml | – sequence: 1 givenname: T. orcidid: 0000-0002-1466-8875 surname: Zuberbier fullname: Zuberbier, T. email: torsten.zuberbier@charite.de organization: Allergy‐Centre‐Charité – sequence: 2 givenname: W. surname: Aberer fullname: Aberer, W. organization: Medical University of Graz – sequence: 3 givenname: R. orcidid: 0000-0002-8277-1700 surname: Asero fullname: Asero, R. organization: Clinica San Carlo – sequence: 4 givenname: A. H. surname: Abdul Latiff fullname: Abdul Latiff, A. H. organization: Pantai Hospital Kuala Lumpur – sequence: 5 givenname: D. surname: Baker fullname: Baker, D. organization: Baker Allergy Asthma and Dermatology Clinic – sequence: 6 givenname: B. surname: Ballmer‐Weber fullname: Ballmer‐Weber, B. organization: University Hospital – sequence: 7 givenname: J. A. orcidid: 0000-0002-3476-1196 surname: Bernstein fullname: Bernstein, J. A. organization: University of Cincinnati Physicians Immunology Research Center – sequence: 8 givenname: C. surname: Bindslev‐Jensen fullname: Bindslev‐Jensen, C. organization: Odense University Hospital and University of Southern Denmark – sequence: 9 givenname: Z. orcidid: 0000-0002-1230-7013 surname: Brzoza fullname: Brzoza, Z. organization: Medical University of Silesia – sequence: 10 givenname: R. surname: Buense Bedrikow fullname: Buense Bedrikow, R. organization: Santa Casa de Sao Paulo School of Medical Sciences – sequence: 11 givenname: G. W. surname: Canonica fullname: Canonica, G. W. organization: Personalized Medicine Asthma and Allergy Clinic‐Humanitas University & Research Hospital – sequence: 12 givenname: M. K. surname: Church fullname: Church, M. K. organization: Allergy‐Centre‐Charité – sequence: 13 givenname: T. surname: Craig fullname: Craig, T. organization: Hershey Medical Center – sequence: 14 givenname: I. V. surname: Danilycheva fullname: Danilycheva, I. V. organization: National Research Center—Institute of Immunology Federal Medical‐Biological Agency of Russia – sequence: 15 givenname: C. surname: Dressler fullname: Dressler, C. organization: Department of Dermatology – sequence: 16 givenname: L. F. surname: Ensina fullname: Ensina, L. F. organization: Federal University of Sao Paulo – sequence: 17 givenname: A. surname: Giménez‐Arnau fullname: Giménez‐Arnau, A. organization: Universitat Autònoma Barcelona – sequence: 18 givenname: K. surname: Godse fullname: Godse, K. organization: Dr. D. Y. Patil Medical College & Hospital – sequence: 19 givenname: M. surname: Gonçalo fullname: Gonçalo, M. organization: Faculty of Medicine and University Hospital – sequence: 20 givenname: C. surname: Grattan fullname: Grattan, C. organization: NHS Foundation Trust – sequence: 21 givenname: J. surname: Hebert fullname: Hebert, J. organization: Centre Hospitalier Université Laval/Centre Hospitalier Universitaire de Québec – sequence: 22 givenname: M. orcidid: 0000-0001-6183-6467 surname: Hide fullname: Hide, M. organization: Hiroshima University – sequence: 23 givenname: A. surname: Kaplan fullname: Kaplan, A. organization: Medical University of South Carolina – sequence: 24 givenname: A. surname: Kapp fullname: Kapp, A. organization: Hannover Medical School – sequence: 25 givenname: C. H. surname: Katelaris fullname: Katelaris, C. H. organization: Campbelltown Hospital and Western Sydney University – sequence: 26 givenname: E. surname: Kocatürk fullname: Kocatürk, E. organization: Okmeydani Training and Research Hospital – sequence: 27 givenname: K. surname: Kulthanan fullname: Kulthanan, K. organization: Mahidol University – sequence: 28 givenname: D. orcidid: 0000-0002-5713-5331 surname: Larenas‐Linnemann fullname: Larenas‐Linnemann, D. organization: Hospital Médica Sur – sequence: 29 givenname: T. A. surname: Leslie fullname: Leslie, T. A. organization: Royal Free Hospital – sequence: 30 givenname: M. surname: Magerl fullname: Magerl, M. organization: Allergy‐Centre‐Charité – sequence: 31 givenname: P. surname: Mathelier‐Fusade fullname: Mathelier‐Fusade, P. organization: University Hospital of Tenon – sequence: 32 givenname: R. Y. surname: Meshkova fullname: Meshkova, R. Y. organization: Smolensk State Medical University – sequence: 33 givenname: M. surname: Metz fullname: Metz, M. organization: Allergy‐Centre‐Charité – sequence: 34 givenname: A. surname: Nast fullname: Nast, A. organization: Department of Dermatology – sequence: 35 givenname: E. surname: Nettis fullname: Nettis, E. organization: Università di Bari – sequence: 36 givenname: H. surname: Oude‐Elberink fullname: Oude‐Elberink, H. organization: University of Groningen – sequence: 37 givenname: S. surname: Rosumeck fullname: Rosumeck, S. organization: Department of Dermatology – sequence: 38 givenname: S. S. surname: Saini fullname: Saini, S. S. organization: Johns Hopkins Asthma and Allergy Center – sequence: 39 givenname: M. surname: Sánchez‐Borges fullname: Sánchez‐Borges, M. organization: Centro Médico‐Docente La Trinidad – sequence: 40 givenname: P. surname: Schmid‐Grendelmeier fullname: Schmid‐Grendelmeier, P. organization: University Hospital – sequence: 41 givenname: P. surname: Staubach fullname: Staubach, P. organization: University Medical Center Mainz – sequence: 42 givenname: G. surname: Sussman fullname: Sussman, G. organization: University of Toronto – sequence: 43 givenname: E. surname: Toubi fullname: Toubi, E. organization: Faculty of Medicine – sequence: 44 givenname: G. A. surname: Vena fullname: Vena, G. A. organization: Dermatology and Venereology Private Practice – sequence: 45 givenname: C. surname: Vestergaard fullname: Vestergaard, C. organization: Aarhus University Hospital – sequence: 46 givenname: B. surname: Wedi fullname: Wedi, B. organization: Hannover Medical School – sequence: 47 givenname: R. N. surname: Werner fullname: Werner, R. N. organization: Department of Dermatology – sequence: 48 givenname: Z. surname: Zhao fullname: Zhao, Z. organization: First Hospital – sequence: 49 givenname: M. surname: Maurer fullname: Maurer, M. organization: Allergy‐Centre‐Charité |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29336054$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kUFu3CAYhVGVqJkkXfQCFVI3jVTHYIyBpTWdpJGsZJOqS4QxTIkwTsFWlGv1CD1ZaGayiRo2CPS9p_9_7xgchCkYAD5idI7zKZX355gQwd6BFSaCF0IIegBWCCNa1JTwI3Cc0h1CiFUCvQdHlSCkQbRegfH2l4Gbtl1flZft3z_d5rrcfLsof7Y3cLu4wXgXDLRThHPmBmNdcLObwleovUrJWafV7j04tQ1TcgmqMMBRBbU1owkznCxc4py56NQpOLTKJ_Nhf5-AHxeb2_X3oru5vFq3XaFrWrNC1KRp2MA1F0hRzvrKNj2nQvP8q6juFUcU07yEYaiviMWIa8ttpQeieM3ICfiy872P0-_FpFmOLmnjvQpmWpLEggvKmqpqMvr5FXo3LTHk6WSFKKeUMSwy9WlPLf1oBnkf3ajio3wJMgPlDtBxSikaK7Wbn6OZo3JeYiT_VSVzVfK5qqw4e6V4Mf0fu3d_cN48vg3Ktut2iifLyaBi |
| CitedBy_id | crossref_primary_10_1136_bcr_2022_251057 crossref_primary_10_1001_jamapediatrics_2020_1316 crossref_primary_10_1111_ddg_14485_g crossref_primary_10_1136_bmjopen_2020_045027 crossref_primary_10_3389_fmicb_2021_672026 crossref_primary_10_1016_j_rmed_2020_106041 crossref_primary_10_1016_j_imbio_2025_152868 crossref_primary_10_1111_exd_14401 crossref_primary_10_1186_s13052_019_0695_x crossref_primary_10_1111_all_13434 crossref_primary_10_1080_15569527_2021_1945618 crossref_primary_10_15557_PiMR_2024_0001 crossref_primary_10_1111_dth_14397 crossref_primary_10_1007_s00105_021_04816_2 crossref_primary_10_1111_dth_15248 crossref_primary_10_1016_j_jaip_2018_10_025 crossref_primary_10_1016_j_jaip_2021_02_044 crossref_primary_10_3390_pathogens12060777 crossref_primary_10_1016_j_clindermatol_2019_07_035 crossref_primary_10_1016_j_iac_2021_04_011 crossref_primary_10_3390_nu17081359 crossref_primary_10_1111_bjd_17005 crossref_primary_10_1111_bjd_20415 crossref_primary_10_1111_bjd_19425 crossref_primary_10_1080_14656566_2020_1829593 crossref_primary_10_3389_fimmu_2019_00627 crossref_primary_10_1097_ACI_0000000000001006 crossref_primary_10_1111_bjd_20892 crossref_primary_10_1159_000492970 crossref_primary_10_1016_j_jaip_2020_07_043 crossref_primary_10_1111_1346_8138_15740 crossref_primary_10_1016_j_jaip_2020_08_055 crossref_primary_10_4103_ijd_ijd_851_21 crossref_primary_10_1155_2022_5243825 crossref_primary_10_1016_j_jaip_2020_08_052 crossref_primary_10_1111_all_14547 crossref_primary_10_1111_cea_13716 crossref_primary_10_1007_s11655_023_3741_x crossref_primary_10_3389_fmed_2022_926753 crossref_primary_10_1016_j_anai_2018_11_024 crossref_primary_10_1016_j_jaip_2021_10_022 crossref_primary_10_1159_000547551 crossref_primary_10_1016_j_waojou_2022_100716 crossref_primary_10_1111_jdv_20157 crossref_primary_10_1080_09546634_2018_1557886 crossref_primary_10_3390_jpm13071068 crossref_primary_10_1016_j_jaip_2021_02_024 crossref_primary_10_1111_bjd_20639 crossref_primary_10_1016_j_jaip_2018_02_024 crossref_primary_10_1016_j_revmed_2018_12_008 crossref_primary_10_1016_j_jaip_2021_02_026 crossref_primary_10_1016_j_jaip_2021_10_012 crossref_primary_10_1177_23247096211006248 crossref_primary_10_1097_MD_0000000000023301 crossref_primary_10_1159_000494931 crossref_primary_10_1007_s00403_024_03613_w crossref_primary_10_1111_ijcp_14942 crossref_primary_10_1093_mr_roab052 crossref_primary_10_2340_actadv_v101_737 crossref_primary_10_1111_dth_14192 crossref_primary_10_3390_ijms20020444 crossref_primary_10_3389_fphar_2021_603736 crossref_primary_10_1016_j_abd_2020_12_003 crossref_primary_10_1016_j_jaip_2021_03_049 crossref_primary_10_1111_all_13482 crossref_primary_10_1111_cei_13428 crossref_primary_10_1111_all_14577 crossref_primary_10_1016_j_jaip_2023_06_033 crossref_primary_10_1080_15569527_2021_1914076 crossref_primary_10_1016_j_ad_2020_11_016 crossref_primary_10_1159_000502431 crossref_primary_10_1016_j_mpmed_2025_04_011 crossref_primary_10_1016_j_reval_2025_104552 crossref_primary_10_4168_aair_2019_11_5_736 crossref_primary_10_1016_j_jaip_2021_03_038 crossref_primary_10_3389_fphar_2024_1488665 crossref_primary_10_1177_03009858231189298 crossref_primary_10_1111_all_13494 crossref_primary_10_1080_15563650_2019_1634812 crossref_primary_10_1111_all_15431 crossref_primary_10_1111_jdv_16947 crossref_primary_10_3389_fimmu_2019_01700 crossref_primary_10_1007_s40521_023_00333_w crossref_primary_10_1007_s00420_023_02019_x crossref_primary_10_1016_j_iac_2021_04_006 crossref_primary_10_4168_aair_2022_14_1_73 crossref_primary_10_1111_dth_15261 crossref_primary_10_1016_j_jaip_2021_03_034 crossref_primary_10_1111_dth_13086 crossref_primary_10_1016_j_aller_2019_11_007 crossref_primary_10_1007_s40521_019_00223_0 crossref_primary_10_1016_j_jaip_2020_07_058 crossref_primary_10_1016_j_waojou_2023_100815 crossref_primary_10_1002_pbc_30846 crossref_primary_10_2500_aap_2020_41_200040 crossref_primary_10_1007_s12668_022_01007_8 crossref_primary_10_3390_diagnostics14020161 crossref_primary_10_3390_medicina60050704 crossref_primary_10_3389_jcia_2024_12476 crossref_primary_10_1111_cea_13500 crossref_primary_10_3390_cells10082170 crossref_primary_10_1111_ced_14359 crossref_primary_10_1111_1346_8138_14830 crossref_primary_10_4103_ijd_IJD_612_20 crossref_primary_10_1111_dth_13212 crossref_primary_10_1111_pai_13426 crossref_primary_10_1111_ddg_13979_g crossref_primary_10_1111_dth_14543 crossref_primary_10_1111_dth_13458 crossref_primary_10_3390_jcm9082505 crossref_primary_10_1016_j_reval_2022_06_003 crossref_primary_10_3389_fphar_2024_1322788 crossref_primary_10_1111_exd_13705 crossref_primary_10_7759_cureus_48358 crossref_primary_10_2147_JIR_S455489 crossref_primary_10_3390_nu16050589 crossref_primary_10_1111_dth_14557 crossref_primary_10_1136_bcr_2021_246276 crossref_primary_10_4103_ijd_ijd_89_23 crossref_primary_10_1080_14786419_2022_2122055 crossref_primary_10_1111_all_13600 crossref_primary_10_1093_bjd_ljae067 crossref_primary_10_3389_fmed_2022_998655 crossref_primary_10_1016_j_jaip_2018_12_023 crossref_primary_10_1016_j_jaip_2018_03_007 crossref_primary_10_5021_ad_2019_31_5_585 crossref_primary_10_1016_j_jaip_2023_11_029 crossref_primary_10_1136_bmjopen_2024_091425 crossref_primary_10_1016_j_fander_2025_03_016 crossref_primary_10_1038_s41401_024_01400_x crossref_primary_10_1111_all_13851 crossref_primary_10_1016_j_jaip_2018_04_026 crossref_primary_10_1093_ced_llae441 crossref_primary_10_1111_pai_13209 crossref_primary_10_4168_aair_2021_13_3_357 crossref_primary_10_4274_jtad_galenos_2021_88609 crossref_primary_10_1186_s13223_020_00459_5 crossref_primary_10_3389_fendo_2023_1167890 crossref_primary_10_1111_pai_13692 crossref_primary_10_1186_s13601_019_0294_3 crossref_primary_10_1111_php_13260 crossref_primary_10_1111_dth_14532 crossref_primary_10_2147_CCID_S336617 crossref_primary_10_1111_pai_13674 crossref_primary_10_1111_all_14950 crossref_primary_10_1159_000507218 crossref_primary_10_1016_j_jaip_2018_04_018 crossref_primary_10_1016_j_fander_2025_03_003 crossref_primary_10_1016_j_jaip_2018_04_012 crossref_primary_10_1111_cea_13309 crossref_primary_10_1016_j_jaip_2018_04_013 crossref_primary_10_1177_22799036241243268 crossref_primary_10_1016_j_anai_2020_06_035 crossref_primary_10_1186_s13223_019_0332_7 crossref_primary_10_1080_1744666X_2022_2074402 crossref_primary_10_1111_all_14713 crossref_primary_10_29262_ram_v67i7_777 crossref_primary_10_1016_j_phymed_2020_153391 crossref_primary_10_2174_0115748871307432240930051749 crossref_primary_10_1007_s13318_025_00946_3 crossref_primary_10_1007_s12020_019_02133_2 crossref_primary_10_1097_MD_0000000000015711 crossref_primary_10_1016_j_jaip_2018_04_003 crossref_primary_10_1111_all_13636 crossref_primary_10_1111_all_13878 crossref_primary_10_1186_s13052_020_00843_2 crossref_primary_10_1016_j_jaad_2020_08_035 crossref_primary_10_3892_etm_2019_8126 crossref_primary_10_3892_etm_2019_8367 crossref_primary_10_1016_j_reval_2019_10_006 crossref_primary_10_1111_cea_14462 crossref_primary_10_4168_aair_2020_12_5_750 crossref_primary_10_1111_dth_14356 crossref_primary_10_1016_j_joim_2020_05_004 crossref_primary_10_1093_ced_llad386 crossref_primary_10_1080_09546634_2020_1782326 crossref_primary_10_1016_j_jaip_2020_08_048 crossref_primary_10_1016_j_iac_2024_03_005 crossref_primary_10_1111_ddg_14415_g crossref_primary_10_1016_j_iac_2024_03_004 crossref_primary_10_4168_aair_2023_15_1_32 crossref_primary_10_1016_j_iac_2024_03_003 crossref_primary_10_2147_CCID_S393406 crossref_primary_10_3389_fimmu_2022_853561 crossref_primary_10_1177_12034754221128819 crossref_primary_10_1016_j_ajem_2020_02_025 crossref_primary_10_1016_j_iac_2024_03_001 crossref_primary_10_3389_fpsyt_2021_655802 crossref_primary_10_1186_s13223_018_0255_8 crossref_primary_10_1016_j_jaip_2018_11_018 crossref_primary_10_1080_15569527_2020_1787432 crossref_primary_10_1111_bcp_14923 crossref_primary_10_25259_IJDVL_257_20 crossref_primary_10_1111_all_13414 crossref_primary_10_1111_all_14502 crossref_primary_10_2147_CCID_S501776 crossref_primary_10_1111_cea_14449 crossref_primary_10_3390_cells13030220 crossref_primary_10_1016_j_clim_2023_109247 crossref_primary_10_1016_j_jaip_2025_07_019 crossref_primary_10_1016_j_reval_2019_02_203 crossref_primary_10_1080_14740338_2025_2460453 crossref_primary_10_1080_14712598_2021_1882990 crossref_primary_10_5021_ad_2020_32_4_280 crossref_primary_10_1111_dth_13489 crossref_primary_10_4168_aair_2021_13_3_390 crossref_primary_10_3390_molecules28165979 crossref_primary_10_1111_all_15603 crossref_primary_10_1016_j_reval_2020_04_003 crossref_primary_10_1002_clt2_12121 crossref_primary_10_1111_all_14757 crossref_primary_10_1111_exd_13959 crossref_primary_10_1097_MD_0000000000022014 crossref_primary_10_1097_01_NPR_0000651112_76528_ed crossref_primary_10_1007_s13555_021_00510_2 crossref_primary_10_3389_fimmu_2024_1422541 crossref_primary_10_1016_j_mcna_2019_08_010 crossref_primary_10_1111_all_15175 crossref_primary_10_1002_clt2_12031 crossref_primary_10_1111_bjd_16820 crossref_primary_10_3389_fimmu_2023_1268467 crossref_primary_10_1038_s41577_021_00622_y crossref_primary_10_1111_cea_13297 crossref_primary_10_1016_j_abd_2022_03_003 crossref_primary_10_1007_s00108_020_00837_6 crossref_primary_10_1111_ajd_12975 crossref_primary_10_3389_fphar_2022_982372 crossref_primary_10_1111_dth_13866 crossref_primary_10_3390_ijms21134749 crossref_primary_10_5415_apallergy_0000000000000162 crossref_primary_10_1080_09546634_2018_1561391 crossref_primary_10_1016_j_anai_2020_04_026 crossref_primary_10_1016_j_clim_2020_108444 crossref_primary_10_1016_j_aller_2019_05_003 crossref_primary_10_1056_NEJMe1907122 crossref_primary_10_1002_hsr2_70777 crossref_primary_10_1016_j_anai_2022_07_017 crossref_primary_10_1016_j_waojou_2020_100501 crossref_primary_10_1155_2019_8650398 crossref_primary_10_1093_occmed_kqac092 crossref_primary_10_1089_jir_2020_0256 crossref_primary_10_1007_s40265_020_01387_9 crossref_primary_10_1007_s15007_020_2553_y crossref_primary_10_1007_s11882_022_01033_2 crossref_primary_10_1007_s40272_019_00365_3 crossref_primary_10_1016_j_ad_2021_02_029 crossref_primary_10_2340_actadv_v104_24050 crossref_primary_10_3389_fped_2022_940213 crossref_primary_10_1080_09546634_2018_1515465 crossref_primary_10_3389_fncel_2019_00422 crossref_primary_10_4103_ijd_ijd_718_21 crossref_primary_10_7717_peerj_7404 crossref_primary_10_1111_dth_12993 crossref_primary_10_1111_exd_15023 crossref_primary_10_1007_s13671_019_0258_9 crossref_primary_10_1111_jocd_14851 crossref_primary_10_1016_j_jaip_2019_08_025 crossref_primary_10_1007_s00403_022_02378_4 crossref_primary_10_1016_j_jaip_2020_11_026 crossref_primary_10_12968_bjon_2019_28_3_144 crossref_primary_10_1016_j_anai_2020_05_028 crossref_primary_10_1016_j_carbpol_2025_124143 crossref_primary_10_1007_s15033_020_1853_y crossref_primary_10_1016_j_jaip_2021_04_021 crossref_primary_10_1016_j_jaip_2021_04_023 crossref_primary_10_4168_aair_2020_12_4_563 crossref_primary_10_1097_SLA_0000000000003643 crossref_primary_10_1136_bcr_2020_239243 crossref_primary_10_1016_j_intimp_2022_109437 crossref_primary_10_1016_j_jaip_2020_09_009 crossref_primary_10_1016_j_aller_2020_02_005 crossref_primary_10_1016_j_jaip_2022_01_043 crossref_primary_10_1111_1346_8138_16109 crossref_primary_10_1111_jdv_17385 crossref_primary_10_1016_j_aller_2020_02_007 crossref_primary_10_1111_dth_13663 crossref_primary_10_1186_s13223_018_0288_z crossref_primary_10_1007_s40629_021_00194_2 crossref_primary_10_1080_09546634_2019_1589639 crossref_primary_10_1097_ACI_0000000000000519 crossref_primary_10_2500_aap_2022_43_210111 crossref_primary_10_1007_s00105_018_4318_z crossref_primary_10_1097_ACI_0000000000000513 crossref_primary_10_1016_j_anai_2022_08_003 crossref_primary_10_1186_s13601_019_0278_3 crossref_primary_10_1016_j_clinthera_2018_12_004 crossref_primary_10_5021_ad_24_020 crossref_primary_10_1016_j_adengl_2021_07_002 crossref_primary_10_1111_jdv_17131 crossref_primary_10_1056_NEJMoa1900408 crossref_primary_10_1111_pai_13929 crossref_primary_10_1038_s41598_022_27115_9 crossref_primary_10_1111_dth_12796 crossref_primary_10_55994_ejcc_1467724 crossref_primary_10_1111_dth_13647 crossref_primary_10_1186_s12948_020_00118_5 crossref_primary_10_1097_ACI_0000000000000538 crossref_primary_10_3390_ijms242015207 crossref_primary_10_1002_clt2_12083 crossref_primary_10_1002_clt2_12085 crossref_primary_10_1111_ddg_14906_g crossref_primary_10_1080_09546634_2018_1550247 crossref_primary_10_1016_j_ad_2019_04_009 crossref_primary_10_1016_j_ymgme_2023_107611 crossref_primary_10_3390_healthcare11101510 crossref_primary_10_4103_ijd_ijd_446_21 crossref_primary_10_1002_biof_1880 crossref_primary_10_1001_jamadermatol_2018_3447 crossref_primary_10_1155_2020_6694191 crossref_primary_10_1111_jdv_16407 crossref_primary_10_4168_aair_2020_12_4_599 crossref_primary_10_1111_pde_15519 crossref_primary_10_4103_NJM_NJM_185_21 crossref_primary_10_2500_aap_2023_44_220093 crossref_primary_10_3389_fnins_2022_1026200 crossref_primary_10_1016_j_intimp_2024_111706 crossref_primary_10_1016_j_adengl_2021_05_020 crossref_primary_10_1016_j_jaip_2021_03_012 crossref_primary_10_1016_j_jaip_2019_10_046 crossref_primary_10_1007_s00105_018_4345_9 crossref_primary_10_1016_j_intimp_2022_109063 crossref_primary_10_1111_all_14015 crossref_primary_10_1111_jdv_17724 crossref_primary_10_18203_issn_2455_4529_IntJResDermatol20252549 crossref_primary_10_2217_imt_2020_0088 crossref_primary_10_4103_abr_abr_426_23 crossref_primary_10_1007_s15007_020_2566_6 crossref_primary_10_1097_ACI_0000000000000556 crossref_primary_10_3390_antibiotics10020156 crossref_primary_10_1016_j_aller_2020_03_011 crossref_primary_10_1016_j_jaip_2020_10_056 crossref_primary_10_1016_j_jdcr_2019_11_013 crossref_primary_10_2147_JAA_S249765 crossref_primary_10_1186_s13223_019_0372_z crossref_primary_10_1016_j_waojou_2020_100107 crossref_primary_10_2340_actadv_v105_43859 crossref_primary_10_1111_cup_13985 crossref_primary_10_1016_j_waojou_2020_100101 crossref_primary_10_1111_all_15592 crossref_primary_10_1016_j_jaip_2019_10_018 crossref_primary_10_1111_all_14024 crossref_primary_10_5812_ircmj_84250 crossref_primary_10_1111_pde_14455 crossref_primary_10_1111_all_15119 crossref_primary_10_2478_jce_2025_0016 crossref_primary_10_1111_all_14027 crossref_primary_10_1111_ijd_17366 crossref_primary_10_1111_1346_8138_16527 crossref_primary_10_1016_j_clindermatol_2019_10_017 crossref_primary_10_1016_j_waojou_2020_100117 crossref_primary_10_1080_13543784_2022_2042513 crossref_primary_10_1051_myolog_202123012 crossref_primary_10_1111_all_14032 crossref_primary_10_1111_all_14037 crossref_primary_10_53126_MEB41263 crossref_primary_10_1016_j_ad_2022_10_033 crossref_primary_10_3389_fimmu_2021_780829 crossref_primary_10_12998_wjcc_v10_i21_7553 crossref_primary_10_3389_falgy_2025_1614277 crossref_primary_10_1016_j_jaip_2021_07_043 crossref_primary_10_1093_ajcp_aqaa134 crossref_primary_10_1016_j_pharmthera_2025_108892 crossref_primary_10_1016_j_reval_2021_03_077 crossref_primary_10_1097_MPH_0000000000001802 crossref_primary_10_1016_j_jtcme_2020_12_003 crossref_primary_10_1016_j_jaip_2023_08_033 crossref_primary_10_1111_bjd_17314 crossref_primary_10_1016_j_chemosphere_2021_132358 crossref_primary_10_1016_j_jaip_2023_09_002 crossref_primary_10_17816_dv624237 crossref_primary_10_1016_j_jaip_2023_09_004 crossref_primary_10_1093_jleuko_qiad025 crossref_primary_10_1111_all_14293 crossref_primary_10_1111_jdv_19940 crossref_primary_10_1111_all_15381 crossref_primary_10_3390_immuno5040044 crossref_primary_10_1016_j_jaip_2020_11_043 crossref_primary_10_1080_03007995_2019_1586222 crossref_primary_10_1186_s13063_019_3878_2 crossref_primary_10_4103_ijd_IJD_557_18 crossref_primary_10_3389_fimmu_2024_1439331 crossref_primary_10_1001_jamadermatol_2021_3237 crossref_primary_10_1016_j_jaip_2024_02_023 crossref_primary_10_1111_dth_12739 crossref_primary_10_4168_aair_2024_16_6_613 crossref_primary_10_1016_j_reval_2023_103347 crossref_primary_10_1016_j_jaip_2023_08_020 crossref_primary_10_1097_MD_0000000000016127 crossref_primary_10_1016_j_jaip_2020_10_013 crossref_primary_10_1016_j_abd_2023_10_002 crossref_primary_10_1111_jdv_15350 crossref_primary_10_1111_all_16243 crossref_primary_10_1016_j_reval_2021_01_006 crossref_primary_10_1177_19458924221097449 crossref_primary_10_7759_cureus_53125 crossref_primary_10_1111_all_14068 crossref_primary_10_1007_s10238_022_00838_9 crossref_primary_10_1056_NEJMc1915041 crossref_primary_10_37349_ei_2025_1003217 crossref_primary_10_1111_1346_8138_15630 crossref_primary_10_2500_aap_2021_42_200088 crossref_primary_10_1016_j_reval_2021_01_003 crossref_primary_10_1016_j_anai_2019_01_023 crossref_primary_10_3389_fpubh_2021_751579 crossref_primary_10_1111_jdv_16410 crossref_primary_10_1111_all_14075 crossref_primary_10_3390_children11010086 crossref_primary_10_1159_000505514 crossref_primary_10_1155_2022_1904598 crossref_primary_10_1016_j_bja_2019_01_020 crossref_primary_10_3390_medicina57101133 crossref_primary_10_1016_j_waojou_2021_100610 crossref_primary_10_1186_s13223_021_00637_z crossref_primary_10_3389_falgy_2025_1657164 crossref_primary_10_1007_s40521_020_00254_y crossref_primary_10_1016_j_jaci_2022_06_027 crossref_primary_10_1186_s12890_022_02138_0 crossref_primary_10_1111_all_14407 crossref_primary_10_1111_1346_8138_15615 crossref_primary_10_1016_j_ad_2018_06_005 crossref_primary_10_1016_j_annder_2021_04_010 crossref_primary_10_1016_j_jaip_2019_12_039 crossref_primary_10_1111_pai_13152 crossref_primary_10_1159_000491530 crossref_primary_10_1080_14712598_2020_1767061 crossref_primary_10_1016_j_jep_2022_115628 crossref_primary_10_1097_DER_0000000000000916 crossref_primary_10_1111_pai_70174 crossref_primary_10_1016_j_jid_2022_03_037 crossref_primary_10_1111_dth_13188 crossref_primary_10_4103_ijd_ijd_770_24 crossref_primary_10_1016_j_jaci_2022_06_016 crossref_primary_10_1111_vox_12773 crossref_primary_10_1186_s13020_022_00642_3 crossref_primary_10_3389_fpsyt_2021_667978 crossref_primary_10_1016_j_reval_2018_02_205 crossref_primary_10_1111_all_14412 crossref_primary_10_1111_jdv_15709 crossref_primary_10_1016_j_annder_2021_04_009 crossref_primary_10_1016_j_jaci_2019_06_010 crossref_primary_10_1111_ijd_14812 crossref_primary_10_1371_journal_pone_0330866 crossref_primary_10_3389_fmed_2021_616015 crossref_primary_10_1016_j_mpmed_2021_03_008 crossref_primary_10_1080_02652048_2020_1771446 crossref_primary_10_1016_j_imbio_2018_11_001 crossref_primary_10_1111_cea_13838 crossref_primary_10_1111_ajd_13283 crossref_primary_10_1007_s40257_023_00833_0 crossref_primary_10_1136_archdischild_2018_315878 crossref_primary_10_1016_j_waojou_2021_100542 crossref_primary_10_25259_IJSA_52_2024 crossref_primary_10_3390_life11121329 crossref_primary_10_1016_j_waojou_2021_100546 crossref_primary_10_1111_ddg_13979 crossref_primary_10_1016_j_jaip_2019_04_031 crossref_primary_10_1186_s12955_019_1087_z crossref_primary_10_1111_all_14674 crossref_primary_10_3389_fphar_2025_1634089 crossref_primary_10_1111_all_13587 crossref_primary_10_1056_NEJMc2016395 crossref_primary_10_3389_fimmu_2022_850993 crossref_primary_10_1016_j_waojou_2021_100533 crossref_primary_10_1016_j_iac_2022_05_012 crossref_primary_10_1186_s40359_023_01284_2 crossref_primary_10_1111_all_14686 crossref_primary_10_1183_23120541_00341_2020 crossref_primary_10_1016_j_jdcr_2022_09_025 crossref_primary_10_3390_children11040449 crossref_primary_10_1111_all_14687 crossref_primary_10_1111_exd_14326 crossref_primary_10_1016_j_allmed_2025_100049 crossref_primary_10_17116_patol20258702130 crossref_primary_10_1016_j_allmed_2025_100046 crossref_primary_10_1016_j_adengl_2018_10_005 crossref_primary_10_1111_pai_13350 crossref_primary_10_3345_kjp_2019_01165 crossref_primary_10_1080_14712598_2020_1691994 crossref_primary_10_1111_dth_14077 crossref_primary_10_2478_amb_2025_0040 crossref_primary_10_1111_all_14213 crossref_primary_10_1186_s40814_021_00841_z crossref_primary_10_1111_all_14453 crossref_primary_10_1186_s13223_019_0339_0 crossref_primary_10_1111_ddg_14415 crossref_primary_10_1016_j_clindermatol_2021_12_010 crossref_primary_10_1111_jocd_14484 crossref_primary_10_1016_j_jaip_2019_05_059 crossref_primary_10_1007_s11882_020_0900_4 crossref_primary_10_1111_ddg_13531_g crossref_primary_10_1016_j_waojou_2022_100658 crossref_primary_10_1016_j_waojou_2022_100627 crossref_primary_10_1016_j_waojou_2022_100629 crossref_primary_10_3389_fgene_2025_1550205 crossref_primary_10_1111_bjd_19561 crossref_primary_10_1111_exd_14785 crossref_primary_10_1111_all_15310 crossref_primary_10_1111_all_14468 crossref_primary_10_1097_MD_0000000000044538 crossref_primary_10_1111_bjd_19312 crossref_primary_10_1016_j_jaip_2019_05_020 crossref_primary_10_1111_ddg_13531 crossref_primary_10_1159_000502521 crossref_primary_10_1016_j_waojou_2021_100587 crossref_primary_10_1111_dth_15386 crossref_primary_10_1097_PEC_0000000000002327 crossref_primary_10_1111_bjd_18240 crossref_primary_10_1038_s41591_021_01537_w crossref_primary_10_1007_s00011_024_01869_6 crossref_primary_10_1080_03007995_2019_1681134 crossref_primary_10_1016_j_waojou_2021_100577 crossref_primary_10_1016_j_waojou_2022_100635 crossref_primary_10_1097_JD9_0000000000000062 crossref_primary_10_3389_fphar_2020_00783 crossref_primary_10_3389_fimmu_2021_681714 crossref_primary_10_1007_s11356_022_22901_4 crossref_primary_10_5812_ircmj_92416 crossref_primary_10_1080_09546634_2018_1527988 crossref_primary_10_1007_s13555_021_00537_5 crossref_primary_10_1016_j_reval_2020_06_002 crossref_primary_10_2500_aap_2021_42_210026 crossref_primary_10_1080_09546634_2018_1551608 crossref_primary_10_2147_JAA_S205709 crossref_primary_10_1016_j_jaip_2019_05_004 crossref_primary_10_1016_j_jaci_2021_12_772 crossref_primary_10_1080_09546634_2018_1527990 crossref_primary_10_3390_ijerph191610011 crossref_primary_10_4168_aair_2021_13_2_206 crossref_primary_10_2217_imt_2021_0251 crossref_primary_10_1155_2019_9157895 crossref_primary_10_1080_09546634_2018_1527992 crossref_primary_10_1007_s10616_023_00574_2 crossref_primary_10_1080_14712598_2021_1907341 crossref_primary_10_20538_1682_0363_2022_3_67_72 crossref_primary_10_1016_j_jdin_2020_03_003 crossref_primary_10_1111_all_13725 crossref_primary_10_1016_j_ad_2021_04_003 crossref_primary_10_1097_MD_0000000000014541 crossref_primary_10_1016_j_jacig_2025_100468 crossref_primary_10_1111_ced_13960 crossref_primary_10_1016_j_jaad_2019_07_097 crossref_primary_10_1016_j_mpdhp_2020_10_011 crossref_primary_10_1111_pai_13325 crossref_primary_10_1111_pai_13324 crossref_primary_10_1177_20552076221140763 crossref_primary_10_1111_ijd_15988 crossref_primary_10_1016_j_anai_2019_11_028 crossref_primary_10_1177_17557380221106802 crossref_primary_10_1111_all_13737 crossref_primary_10_2147_ITT_S266410 crossref_primary_10_1111_imj_14245 crossref_primary_10_1016_j_jaad_2019_07_068 crossref_primary_10_3390_biology11030433 crossref_primary_10_5798_dicletip_1785132 crossref_primary_10_1080_1744666X_2022_2101999 crossref_primary_10_1111_dth_14652 crossref_primary_10_2500_aap_2021_42_210019 crossref_primary_10_1177_1755738019828762 crossref_primary_10_3389_fcimb_2021_703126 crossref_primary_10_3390_ijms26188895 crossref_primary_10_1097_MD_0000000000021093 crossref_primary_10_1111_pai_13319 crossref_primary_10_7759_cureus_26659 crossref_primary_10_1111_imj_16411 crossref_primary_10_3389_fcimb_2022_831489 crossref_primary_10_1016_j_clindermatol_2021_10_008 crossref_primary_10_1002_eji_201948156 crossref_primary_10_1007_s11882_020_00923_7 crossref_primary_10_1007_s00063_018_0483_1 crossref_primary_10_1016_j_jaad_2020_06_997 crossref_primary_10_1177_12034754231191472 crossref_primary_10_1111_srt_13749 crossref_primary_10_1111_dth_14469 crossref_primary_10_1016_j_jaip_2018_06_011 crossref_primary_10_1111_ddg_14485 crossref_primary_10_1080_14712598_2019_1632286 crossref_primary_10_1080_19932820_2024_2420483 crossref_primary_10_1111_all_13754 crossref_primary_10_1016_j_abd_2024_02_006 crossref_primary_10_1016_j_anai_2019_05_003 crossref_primary_10_1186_s13020_025_01137_7 crossref_primary_10_3390_biom10081181 crossref_primary_10_1016_j_jaip_2018_06_027 crossref_primary_10_1016_j_jaip_2019_12_006 crossref_primary_10_1097_MD_0000000000021266 crossref_primary_10_1007_s15006_019_0453_4 crossref_primary_10_2196_48713 crossref_primary_10_1186_s13601_020_00324_z crossref_primary_10_1007_s00403_020_02064_3 crossref_primary_10_3390_diagnostics15111371 crossref_primary_10_2196_54376 crossref_primary_10_3389_fimmu_2021_665491 crossref_primary_10_3390_medicina58050625 crossref_primary_10_1016_j_paed_2020_04_001 crossref_primary_10_7759_cureus_71232 crossref_primary_10_1002_clt2_12011 crossref_primary_10_21307_sjcapp_2021_001 crossref_primary_10_2340_actadv_v105_44220 crossref_primary_10_1016_j_clim_2020_108636 crossref_primary_10_1111_ddg_15557 crossref_primary_10_3389_fimmu_2021_691304 crossref_primary_10_1111_dth_15303 crossref_primary_10_1007_s00403_023_02706_2 crossref_primary_10_1016_j_jaip_2019_07_021 crossref_primary_10_4103_ijd_ijd_558_22 crossref_primary_10_1111_srt_13731 crossref_primary_10_1016_j_mcna_2019_08_007 crossref_primary_10_3889_oamjms_2021_7545 crossref_primary_10_1007_s11869_021_00999_8 crossref_primary_10_3390_healthcare9091144 crossref_primary_10_3390_diagnostics11112150 crossref_primary_10_1007_s00403_020_02162_2 crossref_primary_10_1097_MD_0000000000023226 crossref_primary_10_1016_j_anai_2024_04_023 crossref_primary_10_5114_aoms_202415 crossref_primary_10_1016_j_jaip_2018_05_009 crossref_primary_10_1016_j_abd_2021_01_006 crossref_primary_10_1111_dth_14821 crossref_primary_10_1016_j_waojou_2019_100033 crossref_primary_10_1007_s40521_020_00251_1 crossref_primary_10_7759_cureus_55282 crossref_primary_10_2147_JAA_S292442 crossref_primary_10_1002_clt2_12392 crossref_primary_10_1016_j_anai_2019_08_014 crossref_primary_10_1001_jamadermatol_2018_3715 crossref_primary_10_1016_j_jaci_2025_01_045 crossref_primary_10_1016_j_jaip_2022_07_032 crossref_primary_10_3389_fimmu_2021_742470 crossref_primary_10_1016_j_jaip_2018_05_005 crossref_primary_10_1002_clt2_70040 crossref_primary_10_1159_000504364 crossref_primary_10_1016_j_reval_2019_02_064 crossref_primary_10_1007_s11882_023_01064_3 crossref_primary_10_1111_dth_15928 crossref_primary_10_1111_pai_12967 crossref_primary_10_1186_s13223_020_00461_x crossref_primary_10_1016_j_jaip_2020_03_022 crossref_primary_10_1080_09546634_2020_1818675 crossref_primary_10_3390_ijerph18094911 crossref_primary_10_2500_aap_2024_45_240010 crossref_primary_10_1016_j_ijwd_2021_04_008 crossref_primary_10_29262_ram_v72i2_1452 crossref_primary_10_1111_dth_14800 crossref_primary_10_1007_s00228_024_03725_2 crossref_primary_10_1089_DERM_0000000000000916 crossref_primary_10_1155_2022_4012416 crossref_primary_10_3389_fimmu_2021_722406 crossref_primary_10_1016_j_ad_2021_10_023 crossref_primary_10_2147_CCID_S451117 crossref_primary_10_1016_j_ad_2021_10_029 crossref_primary_10_4168_aair_2019_11_4_470 crossref_primary_10_1016_j_jid_2022_07_012 crossref_primary_10_1186_s40413_018_0216_1 crossref_primary_10_25259_IJDVL_1145_20 crossref_primary_10_1016_j_jaip_2020_03_030 crossref_primary_10_4168_aair_2020_12_5_894 crossref_primary_10_1007_s13555_022_00827_6 crossref_primary_10_2500_aap_2024_45_240023 crossref_primary_10_1007_s00105_020_04604_4 crossref_primary_10_3390_ijms24087491 crossref_primary_10_1016_j_jaip_2025_04_012 crossref_primary_10_1186_s12948_021_00145_w crossref_primary_10_1007_s12016_020_08794_6 crossref_primary_10_1016_j_waojou_2019_100042 crossref_primary_10_1080_09546634_2019_1590522 crossref_primary_10_3390_vetsci10100613 crossref_primary_10_1111_jebm_12604 crossref_primary_10_3389_fped_2019_00213 crossref_primary_10_1007_s40629_022_00235_4 crossref_primary_10_1016_j_iac_2020_06_005 crossref_primary_10_1007_s40629_023_00278_1 crossref_primary_10_1186_s13601_019_0275_6 crossref_primary_10_1016_j_anai_2019_08_465 crossref_primary_10_3166_afmu_2022_0376 crossref_primary_10_1016_j_jaip_2025_05_051 crossref_primary_10_1186_s13601_019_0299_y crossref_primary_10_4168_aair_2021_13_4_545 crossref_primary_10_1111_all_15090 crossref_primary_10_1186_s40360_023_00665_y crossref_primary_10_1016_j_anai_2019_09_025 crossref_primary_10_1016_j_waojou_2019_100079 crossref_primary_10_1007_s13555_023_00955_7 crossref_primary_10_1016_j_jaip_2020_02_012 crossref_primary_10_1007_s12015_020_10059_w crossref_primary_10_1177_0194599820965233 crossref_primary_10_1186_s40413_018_0193_4 crossref_primary_10_1093_bjd_ljaf237 crossref_primary_10_1016_j_jaip_2020_02_017 crossref_primary_10_2147_JAA_S325657 crossref_primary_10_1016_j_jaip_2019_01_026 crossref_primary_10_1111_ijd_15006 crossref_primary_10_3390_ijms20071733 crossref_primary_10_3390_ijms232214466 crossref_primary_10_1007_s15007_021_4932_4 crossref_primary_10_4103_ijd_ijd_648_22 crossref_primary_10_1080_14656566_2020_1830970 crossref_primary_10_1007_s11255_025_04425_1 crossref_primary_10_1097_ACI_0000000000000636 crossref_primary_10_7759_cureus_16950 crossref_primary_10_1016_j_jfma_2022_02_007 crossref_primary_10_1111_jdv_17474 crossref_primary_10_1111_pai_12950 crossref_primary_10_1111_dth_14841 crossref_primary_10_1136_bmjopen_2023_073914 crossref_primary_10_1186_s12955_019_1266_y crossref_primary_10_7759_cureus_33274 crossref_primary_10_1080_09546634_2018_1543844 crossref_primary_10_1080_09546634_2018_1543845 crossref_primary_10_1016_j_waojou_2019_100097 crossref_primary_10_1016_j_jaip_2020_02_038 crossref_primary_10_1007_s00608_020_00778_1 crossref_primary_10_1111_all_13939 crossref_primary_10_1080_15569527_2018_1495227 crossref_primary_10_3389_fimmu_2021_675451 crossref_primary_10_1016_j_jaip_2019_01_048 crossref_primary_10_1007_s00105_024_05346_3 crossref_primary_10_1111_bjd_18901 crossref_primary_10_1016_j_jaci_2018_10_049 crossref_primary_10_1111_jdv_18330 crossref_primary_10_1007_s13555_025_01498_9 crossref_primary_10_1111_jdv_15045 crossref_primary_10_1111_pde_14360 crossref_primary_10_1111_dth_15946 crossref_primary_10_1097_MD_0000000000019924 crossref_primary_10_1177_1203475419888873 crossref_primary_10_1186_s12948_021_00165_6 crossref_primary_10_1111_all_13949 crossref_primary_10_3389_fimmu_2023_1247432 crossref_primary_10_1097_ACI_0000000000000653 crossref_primary_10_1016_j_reval_2022_01_016 crossref_primary_10_1111_1346_8138_17544 crossref_primary_10_1016_j_anai_2018_12_002 crossref_primary_10_1016_j_waojou_2020_100448 crossref_primary_10_1016_j_intimp_2022_109198 crossref_primary_10_2147_ITT_S261416 crossref_primary_10_1097_DER_0000000000000762 crossref_primary_10_1111_all_15214 crossref_primary_10_1080_14656566_2024_2393280 crossref_primary_10_46497_ArchRheumatol_2022_8784 crossref_primary_10_1002_kjm2_12531 crossref_primary_10_25259_IJDVL_1059_2021 crossref_primary_10_1002_ccr3_4188 crossref_primary_10_33920_med_03_2301_07 crossref_primary_10_1016_j_annemergmed_2020_05_025 crossref_primary_10_1080_09546634_2018_1529379 crossref_primary_10_1186_s13223_021_00612_8 crossref_primary_10_3892_etm_2022_11309 crossref_primary_10_1016_j_jaip_2020_06_056 crossref_primary_10_1111_all_16318 crossref_primary_10_33920_med_03_2301_01 crossref_primary_10_1002_smll_202408104 crossref_primary_10_1016_j_jaip_2020_06_057 crossref_primary_10_1016_j_reval_2022_02_229 crossref_primary_10_1097_MD_0000000000021624 crossref_primary_10_26641_2307_0404_2019_4_189327 crossref_primary_10_1016_j_adengl_2020_03_008 crossref_primary_10_4168_aair_2019_11_1_1 crossref_primary_10_5005_jp_journals_10045_00420 crossref_primary_10_3390_life13010152 crossref_primary_10_4168_aair_2022_14_1_131 crossref_primary_10_1016_j_jaip_2020_05_016 crossref_primary_10_1186_s13223_022_00677_z crossref_primary_10_4103_njcp_njcp_321_24 crossref_primary_10_4168_aair_2023_15_4_496 crossref_primary_10_1111_exd_14460 crossref_primary_10_3389_fimmu_2021_652973 crossref_primary_10_1002_jac5_1712 crossref_primary_10_1159_000512373 crossref_primary_10_1111_ddg_15557_g crossref_primary_10_1016_j_waojou_2020_100460 crossref_primary_10_1111_all_14144 crossref_primary_10_1016_j_ymgme_2019_05_006 crossref_primary_10_1111_bcp_15490 crossref_primary_10_1016_j_jaip_2020_05_043 crossref_primary_10_15789_1563_0625_EOL_2928 crossref_primary_10_1016_j_waojou_2020_100475 crossref_primary_10_1016_j_heliyon_2020_e05621 crossref_primary_10_1016_j_waojou_2020_100470 crossref_primary_10_3389_fgene_2025_1560832 crossref_primary_10_3390_jcm14134580 crossref_primary_10_1007_s40257_020_00581_5 crossref_primary_10_1177_1721727X241238954 crossref_primary_10_1016_j_reval_2023_103682 crossref_primary_10_3390_biomedicines10092152 crossref_primary_10_1111_jdv_17659 crossref_primary_10_1111_all_15013 crossref_primary_10_12688_f1000research_16836_3 crossref_primary_10_4168_aair_2021_13_5_746 crossref_primary_10_1001_jamapediatrics_2020_5314 crossref_primary_10_1111_ced_15397 crossref_primary_10_1155_2018_5615109 crossref_primary_10_1111_all_15261 crossref_primary_10_2147_CCID_S350122 crossref_primary_10_1186_s13223_021_00614_6 crossref_primary_10_1016_j_ajem_2020_12_038 crossref_primary_10_1016_j_jid_2021_10_006 crossref_primary_10_1016_j_anai_2021_05_031 crossref_primary_10_3389_fmed_2020_00039 crossref_primary_10_2196_50114 crossref_primary_10_1007_s00403_024_03749_9 crossref_primary_10_1007_s12016_021_08886_x crossref_primary_10_4103_0366_6999_239304 crossref_primary_10_1016_j_jaip_2020_05_056 crossref_primary_10_4168_aair_2021_13_4_521 crossref_primary_10_1007_s40257_020_00561_9 crossref_primary_10_1111_all_15030 crossref_primary_10_1159_000513267 crossref_primary_10_1186_s13052_021_01151_z crossref_primary_10_2500_aap_2024_45_230092 crossref_primary_10_1111_all_15273 crossref_primary_10_1016_j_waojou_2019_100011 crossref_primary_10_1080_03007995_2021_1984220 crossref_primary_10_1016_j_waojou_2019_100013 crossref_primary_10_1016_j_jaci_2018_09_007 crossref_primary_10_1097_MD_0000000000016036 crossref_primary_10_1016_j_jaip_2021_12_031 crossref_primary_10_1016_j_jaip_2022_07_018 crossref_primary_10_1016_j_jaip_2022_08_051 crossref_primary_10_1111_ddg_14906 crossref_primary_10_3389_fmed_2022_899857 crossref_primary_10_1111_all_14192 crossref_primary_10_1111_jdv_15684 crossref_primary_10_3389_fimmu_2022_995596 crossref_primary_10_3390_biomedicines9111615 crossref_primary_10_1136_bcr_2023_259485 crossref_primary_10_1007_s13671_018_0223_z crossref_primary_10_1038_s41467_023_44373_x crossref_primary_10_1177_1203475419847956 crossref_primary_10_1097_MD_0000000000017115 crossref_primary_10_1007_s11882_020_00929_1 crossref_primary_10_1016_j_jaci_2020_03_005 crossref_primary_10_1159_000500196 |
| Cites_doi | 10.1111/bjd.13621 10.1111/j.1398-9995.2007.01591.x 10.1016/S0091-6749(96)80958-4 10.1111/j.1398-9995.2008.01879.x 10.1111/cea.12944 10.1111/all.12313 10.1111/all.12056 10.1111/ced.12107 10.1111/j.1365-2125.2007.02859.x 10.1016/j.aller.2015.10.004 10.1016/j.jaci.2017.01.043 10.1111/j.1398-9995.2009.02325.x 10.1111/1523-1747.ep12499960 10.1046/j.1365-2222.2003.01589.x 10.1111/j.1365-2133.2004.06095.x 10.1007/BF00637746 10.1016/j.jaci.2011.04.038 10.1016/j.vhri.2016.07.008 10.1111/j.1398-9995.2009.02179.x 10.1111/j.1398-9995.2007.01620.x 10.1111/bjd.14203 10.1038/jid.2014.306 10.1067/mjd.2000.104517 10.1186/2045-7022-2-19 10.1080/00015550252948167 10.1136/annrheumdis-2016-209686 10.1016/j.anai.2009.12.007 10.1016/j.jid.2016.11.025 10.1111/j.1398-9995.2009.02132.x 10.2340/0001555576295297 10.1111/jdv.14384 10.2500/aap.2014.35.3764 10.1111/j.1525-1470.2009.00869.x 10.1111/j.1398-9995.2009.02268.x 10.2340/00015555-2573 10.1016/j.jaci.2016.05.026 10.1111/j.1365-2133.1989.tb04167.x 10.1155/2015/368053 10.2500/aap.2016.37.3915 10.1002/iid3.125 10.1159/000451084 10.1016/j.coi.2008.09.005 10.1016/j.jaci.2016.07.047 10.2340/0001555575484487 10.1016/j.jclinepi.2010.09.012 10.2340/0001555557369370 10.1016/j.jaci.2015.12.1342 10.2500/aap.2017.38.4050 10.1111/jdv.14075 10.1001/jamadermatol.2013.8705 10.1111/all.12209 10.1159/000321181 10.2340/00015555-0240 10.1016/0091-6749(71)90083-2 10.1159/000023902 10.1007/s40273-016-0412-1 10.1001/jamadermatol.2017.3183 10.1159/000339869 10.1038/jid.2008.55 10.1111/j.1399-3038.2010.01120.x 10.1016/j.jaad.2006.04.078 10.1016/j.jaci.2006.12.658 10.1111/bjd.14768 10.1111/j.1468-3083.2009.03289.x 10.1034/j.1398-9995.2003.00091.x 10.1111/jdv.12739 10.1111/j.1398-9995.2009.02178.x 10.1111/j.1398-9995.2008.01726.x 10.1111/cea.12900 10.12688/f1000research.11546.1 10.1056/NEJMoa1215372 10.1111/j.1399-3038.2004.00167.x 10.1016/j.jaci.2013.05.013 10.1159/000237648 10.1111/bjd.12991 10.1016/S0091-6749(99)70506-3 10.1016/j.jdermsci.2014.04.007 10.1159/000320233 10.1097/00000372-198912000-00003 10.1111/jdv.13966 10.1016/j.jaci.2017.04.050 10.1159/000292947 10.1159/000453453 10.2340/00015555-2150 10.1111/j.1365-2133.2009.09441.x 10.1056/NEJMcp011186 10.1111/j.1365-2222.2008.03110.x 10.1111/ced.12547 10.1111/all.13209 10.1159/000246281 10.1111/all.12370 10.1111/j.1398-9995.2009.02188.x 10.1111/j.1398-9995.2011.02570.x 10.1111/j.1398-9995.2010.02496.x 10.1111/j.1365-2230.2007.02512.x 10.1111/all.13271 10.3343/alm.2016.36.1.28 10.1111/cea.12870 10.1016/j.jaci.2008.12.008 10.1016/j.reprotox.2008.05.053 10.1046/j.1365-2133.2000.03664.x 10.1034/j.1398-9995.2000.00317.x 10.1111/all.12870 10.1016/j.jaci.2006.04.003 10.1111/j.1365-2133.1981.tb15306.x 10.1016/j.jaci.2013.12.1076 10.1016/j.jaci.2017.01.042 10.1111/j.1398-9995.2010.02409.x 10.1111/all.13414 10.1016/0140-6736(92)90666-Q 10.1016/j.jaci.2009.11.047 10.4103/0976-500X.179355 10.1056/NEJM199506293322608 10.4168/aair.2017.9.3.212 10.1111/j.1398-9995.2011.02580.x 10.1016/j.jaci.2011.06.010 10.1007/s00403-011-1203-3 10.1136/bmj.328.7454.1490 10.2340/0001555565449450 10.1007/978-3-642-85267-1_2 10.2165/00002018-200831090-00006 10.1046/j.1365-2133.2003.05486.x 10.2340/00015555-1434 10.2500/aap.2016.37.4010 10.1016/j.jaci.2015.06.021 10.1007/s40257-015-0134-8 10.1097/01.NPR.0000471366.32982.f2 10.1111/cea.12348 10.1111/j.1365-2125.2006.02810.x 10.1016/j.jaci.2016.08.050 10.1046/j.1365-2133.1998.02033.x 10.1111/pai.12555 10.1016/j.jaad.2008.07.016 10.1111/pai.12460 10.2340/00015555-1918 10.1111/jdv.14034 10.1016/j.jaci.2014.08.025 10.1016/0091-6749(75)90078-0 10.2340/00015555-0434 10.1016/S0190-9622(88)70137-1 10.1007/s40257-015-0152-6 10.1111/j.1398-9995.2008.01913.x 10.1111/j.1398-9995.1980.tb01728.x 10.1016/j.jclinepi.2010.07.015 10.1136/bmj.311.7001.376 10.1046/j.1365-2133.1997.d01-1168.x 10.1016/j.anai.2016.01.016 10.1097/ACI.0b013e32833c79d7 10.1111/all.12818 10.1111/all.12884 10.1038/sj.bjp.0707002 10.1001/archdermatol.2011.682 10.1002/hup.1184 10.1159/000248580 |
| ContentType | Journal Article |
| Copyright | 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. Copyright © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd |
| Copyright_xml | – notice: 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. – notice: Copyright © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd |
| CorporateAuthor | Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA²LEN, IAACI, IADVL, JDA, NVvA, MSAI, ÖGDV, PSA, RAACI, SBD, SFD, SGAI, SGDV, SIAAIC, SIDeMaST, SPDV, TSD, UNBB, UNEV and WAO |
| CorporateAuthor_xml | – name: Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA²LEN, IAACI, IADVL, JDA, NVvA, MSAI, ÖGDV, PSA, RAACI, SBD, SFD, SGAI, SGDV, SIAAIC, SIDeMaST, SPDV, TSD, UNBB, UNEV and WAO |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 |
| DOI | 10.1111/all.13397 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1398-9995 |
| EndPage | 1414 |
| ExternalDocumentID | 29336054 10_1111_all_13397 ALL13397 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article Practice Guideline |
| GeographicLocations | Europe |
| GeographicLocations_xml | – name: Europe |
| GroupedDBID | .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 2WC 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8F7 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAKAS AAMMB AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFNX AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHEFC AHMBA AIACR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOETA ATUGU AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EMOBN EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI TR2 UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WVDHM WXI WXSBR XG1 Y6R ZGI ZXP ZZTAW ~IA ~KM ~WT AAYXX AIQQE CITATION O8X AAHHS ACCFJ AEEZP AEQDE AIWBW AJBDE CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 |
| ID | FETCH-LOGICAL-c4547-943667d8c890a587b2f6b859c867da5cba80515933e70b23f108cf8f2cd3a8473 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 990 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000436104900004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0105-4538 1398-9995 |
| IngestDate | Fri Jul 11 11:55:48 EDT 2025 Fri Oct 03 10:51:20 EDT 2025 Thu Apr 03 07:05:03 EDT 2025 Tue Nov 18 22:20:22 EST 2025 Sat Nov 29 06:24:52 EST 2025 Wed Aug 20 07:26:36 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | consensus hives angioedema wheal evidence-based |
| Language | English |
| License | 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4547-943667d8c890a587b2f6b859c867da5cba80515933e70b23f108cf8f2cd3a8473 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Instructional Material/Guideline-3 content type line 23 |
| ORCID | 0000-0002-1230-7013 0000-0002-3476-1196 0000-0001-6183-6467 0000-0002-1466-8875 0000-0002-5713-5331 0000-0002-8277-1700 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/all.13397 |
| PMID | 29336054 |
| PQID | 2058557719 |
| PQPubID | 34098 |
| PageCount | 22 |
| ParticipantIDs | proquest_miscellaneous_1989576226 proquest_journals_2058557719 pubmed_primary_29336054 crossref_citationtrail_10_1111_all_13397 crossref_primary_10_1111_all_13397 wiley_primary_10_1111_all_13397_ALL13397 |
| PublicationCentury | 2000 |
| PublicationDate | July 2018 |
| PublicationDateYYYYMMDD | 2018-07-01 |
| PublicationDate_xml | – month: 07 year: 2018 text: July 2018 |
| PublicationDecade | 2010 |
| PublicationPlace | Denmark |
| PublicationPlace_xml | – name: Denmark – name: Zurich |
| PublicationTitle | Allergy (Copenhagen) |
| PublicationTitleAlternate | Allergy |
| PublicationYear | 2018 |
| Publisher | Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Publishing Ltd |
| References | 2010; 10 2013; 68 2013; 368 2010; 104 2003; 58 2016; 31 2017; 153 2008; 31 2004; 328 2014; 133 2016; 37 2016; 36 1996; 76 2016; 34 2017; 73 2017; 72 2010; 20 2011; 128 2013; 2013 2015; 135 2015; 136 1980; 35 2017; 76 2011; 64 2008; 26 2011; 66 2009; 123 1988; 177 2008; 20 2007; 63 2007; 64 1989; 36 2016; 44 1989; 3 2009; 64 1988; 18 2006; 55 1998 2008; 59 2016; 96 2013; 93 2008; 128 2014; 150 1995; 311 1999; 103 2002; 82 2010; 162 1998; 138 2006; 117 2017; 137 2014; 44 1996; 97 2017; 139 2003; 33 2016; 11 2016; 4 2016; 7 2007; 150 2004; 151 1989; 120 2015; 2015 1996; 193 2014; 35 2017; 140 2016; 171 2007; 87 2016; 27 2016; 175 2016; 174 2016; 23 1995; 75 2007; 39 1997; 114 2017; 6 2017; 47 1981; 104 1971; 48 2000; 42 2014; 69 1998; 115 2016; 71 1995; 332 1975; 55 2014; 171 2007; 32 1992; 98 2013; 160 1985; 65 2017; 9 2011; 155 2011; 154 2017; 31 2010; 65 2015; 172 2015; 40 2017; 38 2000; 55 2002; 346 2011; 22 2010; 152 2018; 73 2016; 116 2008; 63 2011; 26 2009; 23 1997; 136 2015; 16 2011 2015; 95 2010; 125 2009 2017; 172 2012; 148 2015; 8 2012; 304 2009; 26 2017; 97 1989; 11 2012; 2 2007; 119 2015; 29 2013; 38 2003; 149 2004; 15 1992; 339 2017 2015 2016; 138 2000; 143 2008; 88 2013; 132 2016; 137 1977; 57 2014 2014; 75 2009; 39 e_1_2_10_21_1 e_1_2_10_44_1 e_1_2_10_40_1 e_1_2_10_109_1 e_1_2_10_131_1 Pereira C (e_1_2_10_143_1) 2007; 39 e_1_2_10_158_1 e_1_2_10_70_1 e_1_2_10_93_1 e_1_2_10_2_1 e_1_2_10_139_1 e_1_2_10_18_1 e_1_2_10_74_1 e_1_2_10_97_1 e_1_2_10_116_1 e_1_2_10_150_1 e_1_2_10_6_1 e_1_2_10_55_1 e_1_2_10_14_1 e_1_2_10_37_1 e_1_2_10_78_1 e_1_2_10_112_1 e_1_2_10_154_1 Asero R (e_1_2_10_138_1) 2010; 20 e_1_2_10_13_1 e_1_2_10_32_1 e_1_2_10_51_1 Maurer M (e_1_2_10_169_1) 2014 e_1_2_10_120_1 e_1_2_10_166_1 Laurberg G (e_1_2_10_151_1) 1977; 57 e_1_2_10_128_1 e_1_2_10_29_1 e_1_2_10_63_1 e_1_2_10_105_1 e_1_2_10_124_1 e_1_2_10_162_1 e_1_2_10_25_1 e_1_2_10_48_1 e_1_2_10_67_1 e_1_2_10_101_1 e_1_2_10_45_1 e_1_2_10_22_1 Sand FL (e_1_2_10_146_1) 2013; 2013 e_1_2_10_41_1 Zuberbier T (e_1_2_10_85_1) 1995; 75 e_1_2_10_132_1 e_1_2_10_155_1 e_1_2_10_159_1 e_1_2_10_90_1 e_1_2_10_71_1 e_1_2_10_117_1 e_1_2_10_94_1 e_1_2_10_52_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_75_1 e_1_2_10_113_1 e_1_2_10_136_1 e_1_2_10_38_1 e_1_2_10_98_1 e_1_2_10_56_1 e_1_2_10_79_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_10_1 e_1_2_10_33_1 e_1_2_10_121_1 e_1_2_10_144_1 e_1_2_10_167_1 e_1_2_10_148_1 e_1_2_10_60_1 e_1_2_10_83_1 e_1_2_10_64_1 e_1_2_10_102_1 e_1_2_10_125_1 e_1_2_10_140_1 e_1_2_10_163_1 e_1_2_10_49_1 e_1_2_10_87_1 e_1_2_10_26_1 e_1_2_10_68_1 e_1_2_10_23_1 e_1_2_10_46_1 e_1_2_10_69_1 e_1_2_10_42_1 Engin B (e_1_2_10_149_1) 2008; 88 Maurer M (e_1_2_10_129_1) 2017 Zuberbier T (e_1_2_10_34_1) 2007; 87 e_1_2_10_110_1 e_1_2_10_156_1 Kulthanan K (e_1_2_10_135_1) 2017 e_1_2_10_91_1 e_1_2_10_72_1 e_1_2_10_95_1 e_1_2_10_118_1 e_1_2_10_4_1 Ishaq S (e_1_2_10_82_1) 2015; 8 e_1_2_10_53_1 e_1_2_10_16_1 e_1_2_10_39_1 e_1_2_10_76_1 e_1_2_10_99_1 e_1_2_10_114_1 e_1_2_10_152_1 e_1_2_10_8_1 e_1_2_10_57_1 e_1_2_10_133_1 e_1_2_10_58_1 e_1_2_10_11_1 e_1_2_10_30_1 Bruno G (e_1_2_10_86_1) 1998 e_1_2_10_145_1 e_1_2_10_168_1 e_1_2_10_80_1 Hannuksela M (e_1_2_10_147_1) 1985; 65 e_1_2_10_61_1 e_1_2_10_84_1 e_1_2_10_107_1 e_1_2_10_126_1 Zuberbier T (e_1_2_10_137_1) 1996; 76 e_1_2_10_160_1 e_1_2_10_27_1 e_1_2_10_65_1 e_1_2_10_88_1 e_1_2_10_103_1 e_1_2_10_141_1 e_1_2_10_122_1 e_1_2_10_164_1 e_1_2_10_24_1 e_1_2_10_20_1 e_1_2_10_108_1 e_1_2_10_130_1 e_1_2_10_157_1 Kontou‐Fili KK (e_1_2_10_106_1) 1989; 3 e_1_2_10_92_1 Maurer M (e_1_2_10_119_1) 2017 e_1_2_10_73_1 e_1_2_10_115_1 e_1_2_10_96_1 e_1_2_10_54_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_77_1 e_1_2_10_111_1 e_1_2_10_134_1 e_1_2_10_153_1 e_1_2_10_36_1 Shabrawy RM (e_1_2_10_43_1) 2016; 23 e_1_2_10_12_1 e_1_2_10_35_1 e_1_2_10_9_1 e_1_2_10_59_1 e_1_2_10_31_1 e_1_2_10_50_1 e_1_2_10_81_1 e_1_2_10_62_1 e_1_2_10_104_1 e_1_2_10_127_1 e_1_2_10_161_1 e_1_2_10_28_1 e_1_2_10_66_1 e_1_2_10_100_1 e_1_2_10_123_1 e_1_2_10_142_1 e_1_2_10_165_1 e_1_2_10_47_1 e_1_2_10_89_1 |
| References_xml | – year: 2011 – volume: 8 start-page: 6 issue: Suppl1 year: 2015 end-page: 14 article-title: and gastric cancer: a state of the art review publication-title: Gastroenerol Hepatol Bed Bench – volume: 31 start-page: 650 year: 2016 end-page: 655 article-title: A Popular myth – low‐histamine diet improves chronic spontaneous urticaria – fact or fiction? publication-title: J Eur Acad Dermatol Venereol – volume: 119 start-page: 752 year: 2007 end-page: 754 article-title: Successful treatment of delayed pressure urticaria with anti‐TNF‐alpha publication-title: J Allergy Clin Immunol – volume: 55 start-page: 306 year: 2000 end-page: 308 article-title: Chronic urticaria: a mystery publication-title: Allergy – volume: 115 start-page: 210 year: 1998 end-page: 214 article-title: Differential endothelial adhesion molecule expression in early and late whealing reactions publication-title: Int Arch Allergy Immunol – volume: 37 start-page: 450 year: 2016 end-page: 457 article-title: Clinical and etiologic evaluation of the children with chronic urticaria publication-title: Allergy Asthma Proc – volume: 26 start-page: 19 year: 2008 end-page: 23 article-title: The safety of cetirizine during pregnancy. A prospective observational cohort study publication-title: Reprod Toxicol – volume: 65 start-page: 138 year: 2010 end-page: 139 article-title: Efficacy of omalizumab in delayed pressure urticaria: a case report publication-title: Allergy – volume: 44 start-page: 1053 year: 2014 end-page: 1060 article-title: Calcitonin gene‐related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria publication-title: Clin Exp Allergy – volume: 2 start-page: 19 year: 2012 article-title: A positive serum basophil histamine release assay is a marker for ciclosporin‐responsiveness in patients with chronic spontaneous urticaria publication-title: Clin Transl Allergy – volume: 59 start-page: 752 year: 2008 end-page: 757 article-title: Narrowband ultraviolet B phototherapy is beneficial in antihistamine‐resistant symptomatic dermographism: a pilot study publication-title: J Am Acad Dermatol – volume: 35 start-page: 139 year: 1980 end-page: 141 article-title: Oral sodium cromoglycate in chronic urticaria publication-title: Allergy – volume: 34 start-page: 815 year: 2016 end-page: 827 article-title: Cost utility of omalizumab compared with standard of care for the treatment of chronic spontaneous urticaria publication-title: Pharmacoeconomics – volume: 136 start-page: 197 year: 1997 end-page: 201 article-title: The impact of chronic urticaria on the quality of life publication-title: Br J Dermatol – volume: 71 start-page: 780 year: 2016 end-page: 802 article-title: The definition, diagnostic testing, and management of chronic inducible urticarias – the EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision publication-title: Allergy – volume: 44 start-page: 286 year: 2016 end-page: 291 article-title: A prospective ten‐year follow‐up of patients with chronic urticaria publication-title: Allergol Immunopathol (Madr) – volume: 171 start-page: 81 year: 2016 end-page: 88 article-title: Positive CD63 basophil activation tests are common in children with chronic spontaneous urticaria and linked to high disease activity publication-title: Int Arch Allergy Immunol – volume: 73 start-page: 251 year: 2017 end-page: 255 article-title: Comparison and interpretability of the available urticaria activity scores publication-title: Allergy – volume: 153 start-page: 1221 year: 2017 end-page: 1222 article-title: Chronic urticaria in children – still itching for insight publication-title: JAMA Dermatol – volume: 150 start-page: 288 year: 2014 end-page: 290 article-title: Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria publication-title: JAMA Dermatol – volume: 63 start-page: 534 year: 2007 end-page: 540 article-title: Pharmacokinetics of desloratadine in children between 2 and 11 years of age publication-title: Br J Clin Pharmacol – volume: 64 start-page: 1256 year: 2009 end-page: 1268 article-title: EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria publication-title: Allergy – volume: 117 start-page: 1415 year: 2006 end-page: 1418 article-title: Successful treatment of cold‐induced urticaria/anaphylaxis with anti‐IgE publication-title: J Allergy Clin Immunol – year: 2014 – volume: 332 start-page: 1767 year: 1995 end-page: 1772 article-title: Chronic urticaria publication-title: N Engl J Med – year: 1998 – year: 2017 article-title: The XTEND‐CIU study: long term use of Omalizumab in Chronic Idiopathic Urticaria publication-title: J Allergy Clin Immunol – volume: 65 start-page: 459 year: 2010 end-page: 466 article-title: Risk of first‐generation H(1)‐antihistamines: a GA(2)LEN position paper publication-title: Allergy – volume: 150 start-page: 509 year: 2007 end-page: 518 article-title: Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506 publication-title: Br J Pharmacol – volume: 97 start-page: 524 year: 2017 end-page: 525 article-title: Treatment of refractory chronic spontaneous urticaria with adalimumab publication-title: Acta Derm Venereol – volume: 88 start-page: 247 year: 2008 end-page: 251 article-title: Treatment of chronic urticaria with narrowband ultraviolet B phototherapy: a randomized controlled trial publication-title: Acta Derm Venereol – volume: 311 start-page: 376 year: 1995 end-page: 380 article-title: Consensus methods for medical and health services research publication-title: BMJ – volume: 96 start-page: 56 year: 2016 end-page: 59 article-title: Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic cold urticaria publication-title: Acta Derm Venereol – volume: 68 start-page: 1185 year: 2013 end-page: 1192 article-title: Development, validation and initial results of the angioedema activity score publication-title: Allergy – volume: 154 start-page: 177 year: 2011 end-page: 180 article-title: Anti‐immunoglobulin E treatment of patients with recalcitrant physical urticaria publication-title: Int Arch Allergy Immunol – volume: 38 start-page: 360 year: 2013 end-page: 366 article-title: A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermographism publication-title: Clin Exp Dermatol – volume: 7 start-page: 48 year: 2016 end-page: 50 article-title: Exercise‐induced urticaria, cholinergic urticaria, and Kounis syndrome publication-title: J Pharmacol Pharmacother – volume: 18 start-page: 1289 year: 1988 end-page: 1298 article-title: Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients publication-title: J Am Acad Dermatol – volume: 63 start-page: 1563 year: 2008 end-page: 1565 article-title: Successful treatment of solar urticaria with anti‐immunoglobulin E therapy publication-title: Allergy – volume: 120 start-page: 403 year: 1989 end-page: 408 article-title: Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine publication-title: Br J Dermatol – volume: 138 start-page: 1483 year: 2016 end-page: 1485 article-title: Antihistamine updosing reduces disease activity in patients with difficult‐to‐treat cholinergic urticaria publication-title: J Allergy Clin Immunol – volume: 39 start-page: 116 year: 2009 end-page: 126 article-title: Incremental build‐up food challenge–a new diagnostic approach to evaluate pseudoallergic reactions in chronic urticaria: a pilot study: stepwise food challenge in chronic urticaria publication-title: Clin Exp Allergy – volume: 6 start-page: 1095 year: 2017 article-title: Chronic urticaria: a focus on pathogenesis publication-title: F1000Res – volume: 68 start-page: 27 year: 2013 end-page: 36 article-title: EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria publication-title: Allergy – volume: 97 start-page: 367 year: 1996 article-title: Characterization of naturally occurring pseudoallergens causing chronic urticaria publication-title: J Allergy Clin Immunol – volume: 32 start-page: 740 year: 2007 end-page: 743 article-title: Candida spp. colonization and serum anticandidal antibody levels in patients with chronic urticaria publication-title: Clin Exp Dermatol – volume: 63 start-page: 8 issue: Suppl 86 year: 2008 end-page: 160 article-title: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) publication-title: Allergy – volume: 128 start-page: 202 year: 2011 end-page: 209 article-title: Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase publication-title: J Allergy Clin Immunol – volume: 64 start-page: 1417 year: 2009 end-page: 1426 article-title: EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria publication-title: Allergy – volume: 104 start-page: 369 year: 1981 end-page: 381 article-title: Recurrent urticaria: clinical investigation of 330 patients publication-title: Br J Dermatol – volume: 64 start-page: 395 year: 2011 end-page: 400 article-title: GRADE guidelines: 2. Framing the question and deciding on important outcomes publication-title: J Clin Epidemiol – volume: 47 start-page: 19 year: 2017 end-page: 36 article-title: Potential blood biomarkers in chronic spontaneous urticaria publication-title: Clin Exp Allergy – volume: 149 start-page: 836 year: 2003 end-page: 840 article-title: Effect of high‐dose intravenous immunoglobulin in delayed pressure urticaria publication-title: Br J Dermatol – volume: 75 start-page: 484 year: 1995 end-page: 487 article-title: Pseudoallergen‐free diet in the treatment of chronic urticaria – a prospective study publication-title: Acta Derm Venereol – volume: 69 start-page: e1 year: 2014 end-page: 29 article-title: Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria publication-title: Allergy – volume: 36 start-page: 28 year: 2016 end-page: 35 article-title: Basophil markers for identification and activation in the indirect basophil activation test by flow cytometry for diagnosis of autoimmune urticaria publication-title: Ann Lab Med – volume: 47 start-page: 710 year: 2017 end-page: 718 article-title: How to manage chronic urticaria ‘beyond’ guidelines: a practical algorithm publication-title: Clin Exp Allergy – volume: 139 start-page: 1059 year: 2017 end-page: 1061 article-title: Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria publication-title: J Allergy Clin Immunol – volume: 135 start-page: 67 year: 2015 end-page: 75 article-title: Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo‐controlled study publication-title: J Invest Dermatol – volume: 20 start-page: 709 year: 2008 end-page: 716 article-title: New concepts in chronic urticaria publication-title: Curr Opin Immunol – volume: 26 start-page: 409 year: 2009 end-page: 413 article-title: Experience with cyclosporine in children with chronic idiopathic urticaria publication-title: Pediatr Dermatol – start-page: 85 year: 1998 end-page: 89 – volume: 172 start-page: 40 year: 2017 end-page: 44 article-title: D‐dimer plasma levels parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria publication-title: Int Arch Allergy Immunol – volume: 136 start-page: 245 year: 2015 end-page: 251 article-title: Approaches to the diagnosis and management of patients with a history of nonsteroidal anti‐inflammatory drug‐related urticaria and angioedema publication-title: J Allergy Clin Immunol – volume: 151 start-page: 898 year: 2004 end-page: 902 article-title: Sodium benzoate‐induced repeated episodes of acute urticaria/angio‐oedema: randomized controlled trial publication-title: Br J Dermatol – volume: 3 start-page: 23 year: 1989 end-page: 25 article-title: Therapeutic effect of cetirizine 2 HCl in delayed pressure urticaria publication-title: Health Sci Rev – volume: 152 start-page: 384 year: 2010 end-page: 389 article-title: Heparin and tranexamic Acid therapy may be effective in treatment‐resistant chronic urticaria with elevated d‐dimer: a pilot study publication-title: Int Arch Allergy Immunol – volume: 27 start-page: 493 year: 2016 end-page: 498 article-title: Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases publication-title: Pediatr Allergy Immunol – volume: 175 start-page: 1153 year: 2016 end-page: 1165 article-title: Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta‐analysis publication-title: Br J Dermatol – volume: 87 start-page: 196 year: 2007 end-page: 205 article-title: Urticaria: current opinions about etiology, diagnosis and therapy publication-title: Acta Derm Venereol – volume: 65 start-page: 449 year: 1985 end-page: 450 article-title: Ultraviolet light therapy in chronic urticaria publication-title: Acta Derm Venereol – volume: 304 start-page: 257 year: 2012 end-page: 262 article-title: Effects of low pseudoallergen diet on urticarial activity and leukotriene levels in chronic urticaria publication-title: Arch Dermatol Res – volume: 123 start-page: 672 year: 2009 end-page: 679 article-title: High‐dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard‐dose treatment in patients with acquired cold urticaria: a randomized, placebo‐controlled, crossover study publication-title: J Allergy Clin Immunol – volume: 16 start-page: 313 year: 2015 end-page: 321 article-title: Resource use and costs in an insured population of patients with chronic idiopathic/spontaneous urticaria publication-title: Am J Clin Dermatol – volume: 20 start-page: 386 year: 2010 end-page: 390 article-title: Usefulness of a short course of oral prednisone in antihistamine‐resistant chronic urticaria: a retrospective analysis publication-title: J Investig Allergol Clin Immunol – volume: 104 start-page: 253 year: 2010 end-page: 258 article-title: Effect of high‐dose intravenous immunoglobulin treatment in therapy‐resistant chronic spontaneous urticaria publication-title: Ann Allergy Asthma Immunol – volume: 31 start-page: 1715 year: 2017 end-page: 1721 article-title: Omalizumab substantially improves dermatology‐related quality of life in patients with chronic spontaneous urticaria publication-title: J Eur Acad Dermatol Venereol – volume: 35 start-page: 295 year: 2014 end-page: 302 article-title: Urticaria and bacterial infections publication-title: Allergy Asthma Proc – volume: 71 start-page: 1135 year: 2016 end-page: 1144 article-title: Effect of omalizumab on angioedema in H1 ‐antihistamine‐resistant chronic spontaneous urticaria patients: results from X‐ACT, a randomized controlled trial publication-title: Allergy – year: 2017 article-title: Cyclosporine for chronic spontaneous urticaria: a meta‐analysis and systematic review publication-title: J Allergy Clin Immunol Pract – volume: 2013 start-page: 130905 year: 2013 article-title: TNF‐alpha inhibitors for chronic urticaria: experience in 20 patients publication-title: J Allergy (Cairo) – volume: 116 start-page: 344 year: 2016 end-page: 348 article-title: Association among stress, hypocortisolism, systemic inflammation, and disease severity in chronic urticaria publication-title: Ann Allergy Asthma Immunol – volume: 98 start-page: 800 year: 1992 end-page: 804 article-title: Anti‐inflammatory effect of cyclosporin A on human skin mast cells publication-title: J Invest Dermatol – volume: 71 start-page: 308 year: 2016 end-page: 322 article-title: Chronic spontaneous urticaria and internal parasites–a systematic review publication-title: Allergy – volume: 140 start-page: 864 year: 2017 end-page: 867 article-title: Omalizumab is effective in cold urticaria‐results of a randomized placebo‐controlled trial publication-title: J Allergy Clin Immunol – volume: 125 start-page: 676 year: 2010 end-page: 682 article-title: The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult‐to‐treat urticaria publication-title: J Allergy Clin Immunol – volume: 38 start-page: 222 year: 2017 end-page: 230 article-title: Randomized, placebo‐controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis publication-title: Allergy Asthma Proc – volume: 33 start-page: 337 year: 2003 end-page: 341 article-title: Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity publication-title: Clin Exp Allergy – volume: 42 start-page: 1030 year: 2000 end-page: 1032 article-title: UVA rush hardening for the treatment of solar urticaria publication-title: J Am Acad Dermatol – volume: 346 start-page: 175 year: 2002 end-page: 179 article-title: Clinical practice. Chronic urticaria and angioedema publication-title: N Engl J Med – volume: 64 start-page: 605 year: 2009 end-page: 612 article-title: How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life publication-title: Allergy – volume: 140 start-page: 1710 year: 2017 end-page: 1713 article-title: Responsiveness and minimal important difference of the urticaria control test publication-title: J Allergy Clin Immunol – year: 2009 – volume: 172 start-page: 1294 year: 2015 end-page: 1302 article-title: Elevations in T‐helper‐2‐initiating cytokines (interleukin‐33, interleukin‐25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (‘idiopathic’) urticaria publication-title: Br J Dermatol – volume: 93 start-page: 168 year: 2013 end-page: 174 article-title: Can on‐demand non‐sedating antihistamines improve urticaria symptoms? A double‐blind, randomized, Single‐dose study publication-title: Acta Derm Venereol – volume: 48 start-page: 366 year: 1971 end-page: 371 article-title: Treatment of cold urticaria with cyproheptadine publication-title: J Allergy Clin Immunol – volume: 58 start-page: 621 year: 2003 end-page: 623 article-title: Quality of life and patients’ satisfaction in chronic urticaria and respiratory allergy publication-title: Allergy – volume: 37 start-page: 18 year: 2016 end-page: 22 article-title: Association between urticaria and virus infections: a systematic review publication-title: Allergy Asthma Proc – volume: 133 start-page: 1365 year: 2014 end-page: 1372 article-title: Development and validation of the Urticaria Control Test: a patient‐reported outcome instrument for assessing urticaria control publication-title: J Allergy Clin Immunol – volume: 132 start-page: 101 year: 2013 end-page: 109 article-title: Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy publication-title: J Allergy Clin Immunol – volume: 143 start-page: 365 year: 2000 end-page: 372 article-title: Randomized double‐blind study of cyclosporin in chronic ‘idiopathic’ urticaria publication-title: Br J Dermatol – volume: 160 start-page: 297 year: 2013 end-page: 300 article-title: Anisakis simplex hypersensitivity is associated with chronic urticaria in endemic areas publication-title: Int Arch Allergy Immunol – volume: 22 start-page: 1 year: 2011 end-page: 8 article-title: Chronic spontaneous urticaria in children: itching for insight publication-title: Pediatr Allergy Immunol – volume: 76 start-page: 295 year: 1996 end-page: 297 article-title: Acute urticaria: clinical aspects and therapeutic responsiveness publication-title: Acta Derm Venereol – volume: 64 start-page: 1427 year: 2009 end-page: 1443 article-title: EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria publication-title: Allergy – volume: 40 start-page: 1 year: 2015 end-page: 6 article-title: Helicobacter pylori: a significant and treatable cause of chronic urticaria and angioedema publication-title: Nurse Pract – volume: 4 start-page: 441 year: 2016 end-page: 445 article-title: Basophil Activation Test identifies the patients with Chronic Spontaneous Urticaria suffering the most active disease publication-title: Immun Inflamm Dis – volume: 328 start-page: 1490 year: 2004 article-title: Grading quality of evidence and strength of recommendations publication-title: BMJ – volume: 128 start-page: 567 year: 2011 end-page: U195 article-title: A randomized, placebo‐controlled, dose‐ranging study of single‐dose omalizumab in patients with H‐1‐antihistamine‐refractory chronic idiopathic urticaria publication-title: J Allergy Clin Immunol – volume: 114 start-page: 86 year: 1997 end-page: 89 article-title: Enhanced P‐selectin expression in chronic and dermographic urticaria publication-title: Int Arch Allergy Immunol – volume: 16 start-page: 553 year: 2015 end-page: 558 article-title: Effects of in chronic spontaneous urticaria: results from a retrospective cohort study publication-title: Am J Clin Dermatol – volume: 66 start-page: 1107 year: 2011 end-page: 1113 article-title: Basophil recruitment and activation in inflammatory skin diseases publication-title: Allergy – volume: 36 start-page: 617 year: 1989 end-page: 619 article-title: Suppression of histamine‐induced skin reactions by loratadine and cetirizine diHCl publication-title: Eur J Clin Pharmacol – volume: 368 start-page: 924 year: 2013 end-page: 935 article-title: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria publication-title: N Engl J Med – volume: 138 start-page: 101 year: 1998 end-page: 106 article-title: Intravenous immunoglobulin in autoimmune chronic urticaria publication-title: Br J Dermatol – volume: 31 start-page: 775 year: 2008 end-page: 788 article-title: Risk of hypospadias in offspring of women using loratadine during pregnancy: a systematic review and meta‐analysis publication-title: Drug Saf – volume: 11 start-page: 528 year: 1989 end-page: 533 article-title: Incidence of leukocytoclastic vasculitis in chronic idiopathic urticaria. Study of 100 cases publication-title: Am J Dermatopathol – volume: 9 start-page: 212 year: 2017 end-page: 219 article-title: Prevalence and risk factors of urticaria with a focus on chronic urticaria in children publication-title: Allergy Asthma Immunol Res – volume: 26 start-page: 133 year: 2011 end-page: 139 article-title: Brain histamine H1 receptor occupancy of loratadine measured by positron emission topography: comparison of H1 receptor occupancy and proportional impairment ratio publication-title: Hum Psychopharmacol – volume: 11 start-page: 57 year: 2016 end-page: 59 article-title: Direct medical costs of chronic urticaria in a private health organization of Buenos Aires, Argentina publication-title: Value Health Reg Issues – volume: 73 start-page: 1145 year: 2018 end-page: 1146 article-title: Executive summary: methods and evidence report for the evidence‐ and consensus‐based (S3) Guideline for the definition, classification, diagnosis, and management of urticaria ‐ revision and update 2017 publication-title: Allergy – volume: 55 start-page: 394 year: 1975 end-page: 402 article-title: In vivo studies of mediator release in cold urticaria and cholinergic urticaria publication-title: J Allergy Clin Immunol – volume: 65 start-page: 1494 year: 2010 end-page: 1495 article-title: Antihistamine‐resistant urticaria factitia successfully treated with anti‐immunoglobulin E therapy publication-title: Allergy – volume: 174 start-page: 892 year: 2016 end-page: 894 article-title: ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real‐life clinical practice publication-title: Br J Dermatol – volume: 76 start-page: 942 year: 2017 end-page: 947 article-title: Diagnostic criteria for cryopyrin‐associated periodic syndrome (CAPS) publication-title: Ann Rheum Dis – volume: 31 start-page: e245 year: 2017 end-page: e246 article-title: Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases publication-title: J Eur Acad Dermatol Venereol – volume: 47 start-page: 684 year: 2017 end-page: 692 article-title: H1‐antihistamine‐refractory chronic spontaneous urticaria: it's worse than we thought – first results of the multicenter real‐life AWARE study publication-title: Clin Exp Allergy – volume: 137 start-page: 1742 year: 2016 end-page: 1750 article-title: Omalizumab for the treatment of chronic spontaneous urticaria: a meta‐analysis of randomized clinical trials publication-title: J Allergy Clin Immunol – volume: 27 start-page: 55 year: 2016 end-page: 61 article-title: Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2‐11 years publication-title: Pediatr Allergy Immunol – year: 2015 – volume: 193 start-page: 324 year: 1996 end-page: 327 article-title: Double‐blind crossover study of high‐dose cetirizine in cholinergic urticaria publication-title: Dermatology – volume: 55 start-page: 705 year: 2006 end-page: 709 article-title: Cyclosporine in chronic idiopathic urticaria: a double‐blind, randomized, placebo‐controlled trial publication-title: J Am Acad Dermatol – volume: 66 start-page: 317 year: 2011 end-page: 330 article-title: Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report publication-title: Allergy – volume: 29 start-page: 2043 year: 2015 end-page: 2045 article-title: An improved Peltier effect‐based instrument for critical temperature threshold measurement in cold‐ and heat‐induced urticaria publication-title: J Eur Acad Dermatol Venereol – volume: 82 start-page: 121 year: 2002 end-page: 123 article-title: Acute allergic reactions to Anisakis simplex after ingestion of anchovies publication-title: Acta Derm Venereol – volume: 23 start-page: 67 year: 2016 end-page: 75 article-title: Helicobacter pylori Infection as a risk factor in patients suffering from food allergy and urticaria publication-title: Egypt J Immunol – volume: 339 start-page: 1078 year: 1992 end-page: 1080 article-title: Plasmapheresis for severe, unremitting, chronic urticaria publication-title: Lancet – volume: 69 start-page: 868 year: 2014 end-page: 887 article-title: The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update publication-title: Allergy – volume: 64 start-page: 174 year: 2007 end-page: 184 article-title: Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults publication-title: Br J Clin Pharmacol – volume: 148 start-page: 103 year: 2012 end-page: 108 article-title: Cancer risk in patients with chronic urticaria: a population‐based cohort study publication-title: Arch Dermatol – volume: 39 start-page: 237 year: 2007 end-page: 242 article-title: Low‐dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria publication-title: Eur Ann Allergy Clin Immunol – volume: 95 start-page: 278 year: 2015 end-page: 282 article-title: Temperature thresholds in assessment of the clinical course of acquired cold contact urticaria: a prospective observational one‐year study publication-title: Acta Derm Venereol – volume: 140 start-page: 870 year: 2017 end-page: 873 article-title: Omalizumab is effective in symptomatic dermographism‐results of a randomized placebo‐controlled trial publication-title: J Allergy Clin Immunol – volume: 155 start-page: 367 year: 2011 end-page: 378 article-title: Evidence for clinical safety, efficacy, and parent and physician perceptions of levocetirizine for the treatment of children with allergic disease publication-title: Int Arch Allergy Immunol – volume: 40 start-page: 399 year: 2015 end-page: 403 article-title: Validation of a simplified provocation instrument for diagnosis and threshold testing of symptomatic dermographism publication-title: Clin Exp Dermatol – volume: 65 start-page: 931 year: 2010 end-page: 932 article-title: Effective treatment of refractory severe heat urticaria with omalizumab publication-title: Allergy – volume: 139 start-page: 1772 year: 2017 end-page: 1781 article-title: Autoimmune chronic spontaneous urticaria: what we know and what we do not know publication-title: J Allergy Clin Immunol – volume: 23 start-page: 1088 year: 2009 end-page: 1091 article-title: The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo‐ controlled treatment with rupatadine 10 and 20 mg publication-title: J Eur Acad Dermatol Venereol – volume: 128 start-page: 1956 year: 2008 end-page: 1963 article-title: Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies publication-title: J Invest Dermatol – volume: 10 start-page: 362 year: 2010 end-page: 369 article-title: Effectiveness of eradication in chronic urticaria: evidence‐based analysis using the grading of recommendations assessment, development, and evaluation system publication-title: Curr Opin Allergy Clin Immunol – volume: 75 start-page: 88 year: 2014 end-page: 93 article-title: Development of a standardized pulse‐controlled ergometry test for diagnosing and investigating cholinergic urticaria publication-title: J Dermatol Sci – volume: 2015 start-page: 368053 year: 2015 article-title: Successful and safe treatment of chronic spontaneous urticaria with omalizumab in a woman during two consecutive pregnancies publication-title: Case Rep Med – volume: 63 start-page: 247 year: 2008 end-page: 249 article-title: Successful treatment of cholinergic urticaria with anti‐immunoglobulin E therapy publication-title: Allergy – volume: 63 start-page: 777 year: 2008 end-page: 780 article-title: How to assess disease activity in patients with chronic urticaria? publication-title: Allergy – volume: 135 start-page: 407 year: 2015 end-page: 412 article-title: The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy publication-title: J Allergy Clin Immunol – volume: 15 start-page: 253 year: 2004 end-page: 260 article-title: Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis–a pooled analysis of three studies publication-title: Pediatr Allergy Immunol – volume: 72 start-page: 2005 year: 2017 end-page: 2016 article-title: The burden of chronic spontaneous urticaria is substantial: real‐world evidence from ASSURE‐CSU publication-title: Allergy – volume: 57 start-page: 369 year: 1977 end-page: 370 article-title: Tranexamic acid (Cyklokapron) in chronic urticaria: a double‐blind study publication-title: Acta Derm Venereol – volume: 66 start-page: 840 year: 2011 end-page: 844 article-title: Recommendations for assessing patient‐reported outcomes and health‐related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper publication-title: Allergy – volume: 31 start-page: 1056 year: 2017 end-page: 1063 article-title: Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema publication-title: J Eur Acad Dermatol Venereol – year: 2017 article-title: Omalizumab treatment in chronic inducible urticaria: a systematic review of published evidence publication-title: J Allergy Clin Immunol – volume: 64 start-page: 401 year: 2011 end-page: 406 article-title: GRADE guidelines: 3. Rating the quality of evidence publication-title: J Clin Epidemiol – volume: 162 start-page: 198 year: 2010 end-page: 200 article-title: Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria publication-title: Br J Dermatol – volume: 103 start-page: 307 year: 1999 end-page: 314 article-title: Upregulation of TNF‐alpha and IL‐3 expression in lesional and uninvolved skin in different types of urticaria publication-title: J Allergy Clin Immunol – volume: 137 start-page: 958 year: 2017 end-page: 961 article-title: Effect of omalizumab on blood basophil counts in patients with chronic idiopathic/spontaneous urticaria publication-title: J Invest Dermatol – volume: 177 start-page: 287 year: 1988 end-page: 291 article-title: Calcium antagonist in the treatment of symptomatic dermographism. Low‐dose and high‐dose studies with nifedipine publication-title: Dermatologica – volume: 171 start-page: 505 year: 2014 end-page: 511 article-title: Elevations in vascular markers and eosinophils in chronic spontaneous urticarial weals with low‐level persistence in uninvolved skin publication-title: Br J Dermatol – ident: e_1_2_10_17_1 doi: 10.1111/bjd.13621 – ident: e_1_2_10_121_1 doi: 10.1111/j.1398-9995.2007.01591.x – ident: e_1_2_10_91_1 doi: 10.1016/S0091-6749(96)80958-4 – ident: e_1_2_10_123_1 doi: 10.1111/j.1398-9995.2008.01879.x – ident: e_1_2_10_139_1 doi: 10.1111/cea.12944 – volume-title: UpToDate year: 2014 ident: e_1_2_10_169_1 – ident: e_1_2_10_4_1 doi: 10.1111/all.12313 – ident: e_1_2_10_48_1 doi: 10.1111/all.12056 – ident: e_1_2_10_73_1 doi: 10.1111/ced.12107 – ident: e_1_2_10_158_1 doi: 10.1111/j.1365-2125.2007.02859.x – ident: e_1_2_10_42_1 doi: 10.1016/j.aller.2015.10.004 – ident: e_1_2_10_69_1 doi: 10.1016/j.jaci.2017.01.043 – ident: e_1_2_10_101_1 doi: 10.1111/j.1398-9995.2009.02325.x – year: 2017 ident: e_1_2_10_119_1 article-title: Omalizumab treatment in chronic inducible urticaria: a systematic review of published evidence publication-title: J Allergy Clin Immunol – ident: e_1_2_10_131_1 doi: 10.1111/1523-1747.ep12499960 – ident: e_1_2_10_54_1 doi: 10.1046/j.1365-2222.2003.01589.x – ident: e_1_2_10_94_1 doi: 10.1111/j.1365-2133.2004.06095.x – ident: e_1_2_10_104_1 doi: 10.1007/BF00637746 – ident: e_1_2_10_114_1 doi: 10.1016/j.jaci.2011.04.038 – ident: e_1_2_10_31_1 doi: 10.1016/j.vhri.2016.07.008 – ident: e_1_2_10_2_1 doi: 10.1111/j.1398-9995.2009.02179.x – ident: e_1_2_10_102_1 doi: 10.1111/j.1398-9995.2007.01620.x – ident: e_1_2_10_27_1 doi: 10.1111/bjd.14203 – ident: e_1_2_10_115_1 doi: 10.1038/jid.2014.306 – ident: e_1_2_10_97_1 doi: 10.1067/mjd.2000.104517 – ident: e_1_2_10_52_1 doi: 10.1186/2045-7022-2-19 – ident: e_1_2_10_12_1 – ident: e_1_2_10_40_1 doi: 10.1080/00015550252948167 – ident: e_1_2_10_79_1 doi: 10.1136/annrheumdis-2016-209686 – volume: 20 start-page: 386 year: 2010 ident: e_1_2_10_138_1 article-title: Usefulness of a short course of oral prednisone in antihistamine‐resistant chronic urticaria: a retrospective analysis publication-title: J Investig Allergol Clin Immunol – ident: e_1_2_10_144_1 doi: 10.1016/j.anai.2009.12.007 – ident: e_1_2_10_56_1 doi: 10.1016/j.jid.2016.11.025 – ident: e_1_2_10_47_1 doi: 10.1111/j.1398-9995.2009.02132.x – volume: 76 start-page: 295 year: 1996 ident: e_1_2_10_137_1 article-title: Acute urticaria: clinical aspects and therapeutic responsiveness publication-title: Acta Derm Venereol doi: 10.2340/0001555576295297 – ident: e_1_2_10_7_1 – ident: e_1_2_10_10_1 doi: 10.1111/jdv.14384 – ident: e_1_2_10_39_1 doi: 10.2500/aap.2014.35.3764 – ident: e_1_2_10_136_1 doi: 10.1111/j.1525-1470.2009.00869.x – ident: e_1_2_10_124_1 doi: 10.1111/j.1398-9995.2009.02268.x – ident: e_1_2_10_145_1 doi: 10.2340/00015555-2573 – ident: e_1_2_10_67_1 doi: 10.1016/j.jaci.2016.05.026 – ident: e_1_2_10_153_1 doi: 10.1111/j.1365-2133.1989.tb04167.x – ident: e_1_2_10_167_1 doi: 10.1155/2015/368053 – ident: e_1_2_10_38_1 doi: 10.2500/aap.2016.37.3915 – ident: e_1_2_10_49_1 doi: 10.1002/iid3.125 – ident: e_1_2_10_50_1 doi: 10.1159/000451084 – ident: e_1_2_10_100_1 doi: 10.1016/j.coi.2008.09.005 – ident: e_1_2_10_53_1 doi: 10.1016/j.jaci.2016.07.047 – volume: 75 start-page: 484 year: 1995 ident: e_1_2_10_85_1 article-title: Pseudoallergen‐free diet in the treatment of chronic urticaria – a prospective study publication-title: Acta Derm Venereol doi: 10.2340/0001555575484487 – ident: e_1_2_10_9_1 doi: 10.1016/j.jclinepi.2010.09.012 – volume: 57 start-page: 369 year: 1977 ident: e_1_2_10_151_1 article-title: Tranexamic acid (Cyklokapron) in chronic urticaria: a double‐blind study publication-title: Acta Derm Venereol doi: 10.2340/0001555557369370 – ident: e_1_2_10_118_1 doi: 10.1016/j.jaci.2015.12.1342 – ident: e_1_2_10_156_1 doi: 10.2500/aap.2017.38.4050 – ident: e_1_2_10_128_1 doi: 10.1111/jdv.14075 – ident: e_1_2_10_130_1 doi: 10.1001/jamadermatol.2013.8705 – ident: e_1_2_10_61_1 doi: 10.1111/all.12209 – ident: e_1_2_10_160_1 doi: 10.1159/000321181 – volume: 87 start-page: 196 year: 2007 ident: e_1_2_10_34_1 article-title: Urticaria: current opinions about etiology, diagnosis and therapy publication-title: Acta Derm Venereol doi: 10.2340/00015555-0240 – ident: e_1_2_10_107_1 doi: 10.1016/0091-6749(71)90083-2 – ident: e_1_2_10_14_1 doi: 10.1159/000023902 – ident: e_1_2_10_33_1 doi: 10.1007/s40273-016-0412-1 – volume: 23 start-page: 67 year: 2016 ident: e_1_2_10_43_1 article-title: Helicobacter pylori Infection as a risk factor in patients suffering from food allergy and urticaria publication-title: Egypt J Immunol – ident: e_1_2_10_78_1 doi: 10.1001/jamadermatol.2017.3183 – ident: e_1_2_10_41_1 doi: 10.1159/000339869 – ident: e_1_2_10_55_1 doi: 10.1038/jid.2008.55 – ident: e_1_2_10_77_1 doi: 10.1111/j.1399-3038.2010.01120.x – ident: e_1_2_10_134_1 doi: 10.1016/j.jaad.2006.04.078 – ident: e_1_2_10_140_1 doi: 10.1016/j.jaci.2006.12.658 – ident: e_1_2_10_112_1 doi: 10.1111/bjd.14768 – ident: e_1_2_10_111_1 doi: 10.1111/j.1468-3083.2009.03289.x – year: 2017 ident: e_1_2_10_129_1 article-title: The XTEND‐CIU study: long term use of Omalizumab in Chronic Idiopathic Urticaria publication-title: J Allergy Clin Immunol – ident: e_1_2_10_30_1 doi: 10.1034/j.1398-9995.2003.00091.x – ident: e_1_2_10_71_1 doi: 10.1111/jdv.12739 – ident: e_1_2_10_3_1 doi: 10.1111/j.1398-9995.2009.02178.x – ident: e_1_2_10_59_1 doi: 10.1111/j.1398-9995.2008.01726.x – ident: e_1_2_10_26_1 doi: 10.1111/cea.12900 – ident: e_1_2_10_36_1 doi: 10.12688/f1000research.11546.1 – ident: e_1_2_10_116_1 doi: 10.1056/NEJMoa1215372 – ident: e_1_2_10_159_1 doi: 10.1111/j.1399-3038.2004.00167.x – ident: e_1_2_10_117_1 doi: 10.1016/j.jaci.2013.05.013 – ident: e_1_2_10_19_1 doi: 10.1159/000237648 – ident: e_1_2_10_20_1 doi: 10.1111/bjd.12991 – ident: e_1_2_10_23_1 doi: 10.1016/S0091-6749(99)70506-3 – start-page: 85 volume-title: Proceedings of the international symposium on urticaria year: 1998 ident: e_1_2_10_86_1 – ident: e_1_2_10_74_1 doi: 10.1016/j.jdermsci.2014.04.007 – ident: e_1_2_10_120_1 doi: 10.1159/000320233 – ident: e_1_2_10_15_1 doi: 10.1097/00000372-198912000-00003 – ident: e_1_2_10_96_1 doi: 10.1111/jdv.13966 – ident: e_1_2_10_62_1 doi: 10.1016/j.jaci.2017.04.050 – ident: e_1_2_10_155_1 doi: 10.1159/000292947 – ident: e_1_2_10_58_1 doi: 10.1159/000453453 – ident: e_1_2_10_65_1 doi: 10.2340/00015555-2150 – ident: e_1_2_10_66_1 doi: 10.1111/j.1365-2133.2009.09441.x – ident: e_1_2_10_22_1 doi: 10.1056/NEJMcp011186 – ident: e_1_2_10_93_1 doi: 10.1111/j.1365-2222.2008.03110.x – ident: e_1_2_10_72_1 doi: 10.1111/ced.12547 – volume: 39 start-page: 237 year: 2007 ident: e_1_2_10_143_1 article-title: Low‐dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria publication-title: Eur Ann Allergy Clin Immunol – ident: e_1_2_10_28_1 doi: 10.1111/all.13209 – volume: 8 start-page: 6 issue: 1 year: 2015 ident: e_1_2_10_82_1 article-title: Helicobacter pylori and gastric cancer: a state of the art review publication-title: Gastroenerol Hepatol Bed Bench – ident: e_1_2_10_105_1 doi: 10.1159/000246281 – ident: e_1_2_10_5_1 doi: 10.1111/all.12370 – ident: e_1_2_10_126_1 doi: 10.1111/j.1398-9995.2009.02188.x – ident: e_1_2_10_16_1 doi: 10.1111/j.1398-9995.2011.02570.x – ident: e_1_2_10_24_1 doi: 10.1111/j.1398-9995.2010.02496.x – ident: e_1_2_10_84_1 doi: 10.1111/j.1365-2230.2007.02512.x – ident: e_1_2_10_60_1 doi: 10.1111/all.13271 – ident: e_1_2_10_51_1 doi: 10.3343/alm.2016.36.1.28 – ident: e_1_2_10_57_1 doi: 10.1111/cea.12870 – ident: e_1_2_10_110_1 doi: 10.1016/j.jaci.2008.12.008 – ident: e_1_2_10_163_1 doi: 10.1016/j.reprotox.2008.05.053 – ident: e_1_2_10_133_1 doi: 10.1046/j.1365-2133.2000.03664.x – ident: e_1_2_10_92_1 doi: 10.1034/j.1398-9995.2000.00317.x – ident: e_1_2_10_127_1 doi: 10.1111/all.12870 – ident: e_1_2_10_122_1 doi: 10.1016/j.jaci.2006.04.003 – ident: e_1_2_10_90_1 doi: 10.1111/j.1365-2133.1981.tb15306.x – ident: e_1_2_10_63_1 doi: 10.1016/j.jaci.2013.12.1076 – ident: e_1_2_10_68_1 doi: 10.1016/j.jaci.2017.01.042 – ident: e_1_2_10_125_1 doi: 10.1111/j.1398-9995.2010.02409.x – ident: e_1_2_10_6_1 doi: 10.1111/all.13414 – ident: e_1_2_10_89_1 doi: 10.1016/0140-6736(92)90666-Q – ident: e_1_2_10_109_1 doi: 10.1016/j.jaci.2009.11.047 – ident: e_1_2_10_88_1 doi: 10.4103/0976-500X.179355 – year: 2017 ident: e_1_2_10_135_1 article-title: Cyclosporine for chronic spontaneous urticaria: a meta‐analysis and systematic review publication-title: J Allergy Clin Immunol Pract – ident: e_1_2_10_21_1 doi: 10.1056/NEJM199506293322608 – ident: e_1_2_10_76_1 doi: 10.4168/aair.2017.9.3.212 – ident: e_1_2_10_25_1 doi: 10.1111/j.1398-9995.2011.02580.x – ident: e_1_2_10_113_1 doi: 10.1016/j.jaci.2011.06.010 – ident: e_1_2_10_95_1 doi: 10.1007/s00403-011-1203-3 – volume: 3 start-page: 23 year: 1989 ident: e_1_2_10_106_1 article-title: Therapeutic effect of cetirizine 2 HCl in delayed pressure urticaria publication-title: Health Sci Rev – ident: e_1_2_10_11_1 doi: 10.1136/bmj.328.7454.1490 – volume: 65 start-page: 449 year: 1985 ident: e_1_2_10_147_1 article-title: Ultraviolet light therapy in chronic urticaria publication-title: Acta Derm Venereol doi: 10.2340/0001555565449450 – ident: e_1_2_10_83_1 doi: 10.1007/978-3-642-85267-1_2 – ident: e_1_2_10_164_1 doi: 10.2165/00002018-200831090-00006 – ident: e_1_2_10_142_1 doi: 10.1046/j.1365-2133.2003.05486.x – ident: e_1_2_10_99_1 doi: 10.2340/00015555-1434 – ident: e_1_2_10_75_1 doi: 10.2500/aap.2016.37.4010 – volume: 2013 start-page: 130905 year: 2013 ident: e_1_2_10_146_1 article-title: TNF‐alpha inhibitors for chronic urticaria: experience in 20 patients publication-title: J Allergy (Cairo) – ident: e_1_2_10_80_1 doi: 10.1016/j.jaci.2015.06.021 – ident: e_1_2_10_32_1 doi: 10.1007/s40257-015-0134-8 – ident: e_1_2_10_45_1 doi: 10.1097/01.NPR.0000471366.32982.f2 – ident: e_1_2_10_18_1 doi: 10.1111/cea.12348 – ident: e_1_2_10_8_1 – ident: e_1_2_10_157_1 doi: 10.1111/j.1365-2125.2006.02810.x – ident: e_1_2_10_35_1 doi: 10.1016/j.jaci.2016.08.050 – ident: e_1_2_10_141_1 doi: 10.1046/j.1365-2133.1998.02033.x – ident: e_1_2_10_162_1 doi: 10.1111/pai.12555 – ident: e_1_2_10_148_1 doi: 10.1016/j.jaad.2008.07.016 – ident: e_1_2_10_161_1 doi: 10.1111/pai.12460 – ident: e_1_2_10_64_1 doi: 10.2340/00015555-1918 – ident: e_1_2_10_166_1 doi: 10.1111/jdv.14034 – ident: e_1_2_10_165_1 doi: 10.1016/j.jaci.2014.08.025 – ident: e_1_2_10_108_1 doi: 10.1016/0091-6749(75)90078-0 – volume: 88 start-page: 247 year: 2008 ident: e_1_2_10_149_1 article-title: Treatment of chronic urticaria with narrowband ultraviolet B phototherapy: a randomized controlled trial publication-title: Acta Derm Venereol doi: 10.2340/00015555-0434 – ident: e_1_2_10_154_1 doi: 10.1016/S0190-9622(88)70137-1 – ident: e_1_2_10_44_1 doi: 10.1007/s40257-015-0152-6 – ident: e_1_2_10_98_1 doi: 10.1111/j.1398-9995.2008.01913.x – ident: e_1_2_10_150_1 doi: 10.1111/j.1398-9995.1980.tb01728.x – ident: e_1_2_10_168_1 doi: 10.1016/j.jclinepi.2010.07.015 – ident: e_1_2_10_13_1 doi: 10.1136/bmj.311.7001.376 – ident: e_1_2_10_29_1 doi: 10.1046/j.1365-2133.1997.d01-1168.x – ident: e_1_2_10_87_1 doi: 10.1016/j.anai.2016.01.016 – ident: e_1_2_10_81_1 doi: 10.1097/ACI.0b013e32833c79d7 – ident: e_1_2_10_37_1 doi: 10.1111/all.12818 – ident: e_1_2_10_70_1 doi: 10.1111/all.12884 – ident: e_1_2_10_132_1 doi: 10.1038/sj.bjp.0707002 – ident: e_1_2_10_46_1 doi: 10.1001/archdermatol.2011.682 – ident: e_1_2_10_103_1 doi: 10.1002/hup.1184 – ident: e_1_2_10_152_1 doi: 10.1159/000248580 |
| SSID | ssj0007290 |
| Score | 2.706208 |
| Snippet | This evidence‐ and consensus‐based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment,... This evidence- and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment,... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1393 |
| SubjectTerms | Allergies Angioedema Asthma consensus Dermatitis Dermatology Disease Management Edema Europe evidence‐based Health Services Needs and Demand hives Humans Medical diagnosis Quality of life Urticaria Urticaria - diagnosis Urticaria - etiology Urticaria - therapy wheal |
| Title | The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fall.13397 https://www.ncbi.nlm.nih.gov/pubmed/29336054 https://www.proquest.com/docview/2058557719 https://www.proquest.com/docview/1989576226 |
| Volume | 73 |
| WOSCitedRecordID | wos000436104900004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1398-9995 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007290 issn: 0105-4538 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1398-9995 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007290 issn: 0105-4538 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB7xEuql5Vm2BWRQDxwIm42T2BanCHYBKSyo4rG3yHZitNKSRYTtD-tP4JcxTrIRCJAq9RYnE9nyzNjfZ4_HAL-0DkOXy9DRNECCwlTqCC9QjjRMaMNTqsukPjcx6_f5YCAuZ-Bwehamyg_RLLhZzyjHa-vgUhWvnFyORgdIsASbhXl7qAqZ1_zx79513AzErF5iQQjh-OjYdWIhG8jT_Px2OnqHMd9C1nLO6X37r9YuwdcaapKoso1lmMnyFVg8rzfTV-EeTYR0o-jorH0SPf-Nu_1297jXvo0uyN3EZr9CKYKYliBGJGlmhnkZ3rVPtEXcNsRIVuW0CtcbFkTmKblvAmrI2JCJrR35uFyD61736ujUqW9fcLRN8uUIn4YhS7nmwpUBZ8ozoeKB0BzfykArye39MILSjLnKo6bjctSu8XRKJc55dB3m8nGebQAJQ-nbLbxASM_PVCpwHDEa_886KnBd04K9qRISXacmtzdkjJIpRcHuS8rua8FuI_pQ5eP4SGhzqsmkdski8VxkRgFjHdGCneYzOpPdIZF5Np4UiQ0gQwKGkLQF3ysLaGpBXESR-_nY2FLRn1efRHFcPvz4d9Gf8AWhGK8CgTdh7ulxkm3Bgv7zNCwet2GWDfh2bd9Yuj3rvwAUrvtn |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB7BgmgvPFvYlodBHDg03Wyc-CH1EsEuIMKCELTcIseJq5WWbMWy_DB-Qn8Z4yQbgQAJiVsSj2XLM2N_nz0ZA-xqzZgrFHM0DZCg8CR1pBckjjJcaiNSqoukPr8j3uuJ62t5PgW_Jv_ClPkh6g036xnFfG0d3G5IP_FyNRj8RIYl-TTM-Ixy0YCZg4vuVVTPxLzaY0EM4fjo2VVmIRvJU1d-vh69AJnPMWux6HQXPtbdRZivwCYJS-tYgqksX4a50-o4fQVu0EhIJwz3j1uH4f-HqNNrdQ66rT_hGfk7tvmvUIogqiWIEkmamX5eBHj9INpibhtkpMr3tAzY64-IylNyU4fUkKEhY9s6MnL1Ba66ncv9I6e6f8HRNs2XI33KGE-FFtJVgeCJZ1giAqkFflWBTpSwN8RISjPuJh41bVegfo2nU6pw1aNfoZEP82wNCGPKt4d4gVSenyWpxJnEaKyftZPAdU0T9iZaiHWVnNzekTGIJyQFhy8uhq8JO7XovzIjx2tC6xNVxpVTjmLPRW4UcN6WTdiui9Gd7BmJyrPheBTbEDKkYAhKm7BamkDdCiIjiuzPx84Wmn67-TiMouLh2_tFt-DT0eVpFEfHvZPv8BmBmSjDgtehcXc7zjZgVt_f9Ue3m5WZPwJPxP1g |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fb9MwED91A1W8jH-DlW1g0B54WNY0TmJb4iXqWqgI2R5g61vk-A-q1KXTuvLB-Ah8sp2TNFoFSEi8JfFZtnx39u_sX84AR0rFsc9l7CkaYYDCCu2JICo8aZlQlmuqqqQ-FynLMj6divMOfFj_C1Pnh2g33JxnVPO1c3Bzre09L5fz-QlGWIJtwYMQcbgjdF1OsnYeZs0OCyIIL0S_bvIKOR5PW3VzNfoNYm4i1mrJGT_-v84-gZ0GapKkto2n0DHlM-h-aQ7Tn8MVmggZJclw0v-Y_PqZjrL-6HTcv0zOyPeVy36FUgQxLUGMSLSxs7Kidx0T5RC3oxjJ-l3XdL3ZkshSk6uWUEMWlqxc6xiPy134Nh59HX7ymtsXPOWSfHkipHHMNFdc-DLirAhsXPBIKI5fZaQKyd39MIJSw_wioHbgc9SuDZSmEtc8-gK2y0Vp9oDEsQzdEV4kZBCaQgucR6zC-mZQRL5ve_B-rYVcNanJ3Q0Z83wdouDw5dXw9eBdK3pd5-P4k9DBWpV545LLPPAxMooYG4gevG2L0ZncCYkszWK1zB2BDAMwhKQ9eFmbQNsK4iKKsV-Ina00_ffm8yRNq4dX_y76Brrnp-M8nWSf9-ERojJec4IPYPv2ZmUO4aH6cTtb3ryubPwO8f_7tg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+EAACI%2FGA%C2%B2LEN%2FEDF%2FWAO+guideline+for+the+definition%2C+classification%2C+diagnosis+and+management+of+urticaria&rft.jtitle=Allergy+%28Copenhagen%29&rft.au=Zuberbier%2C+T.&rft.au=Aberer%2C+W.&rft.au=Asero%2C+R.&rft.au=Abdul+Latiff%2C+A.+H.&rft.date=2018-07-01&rft.issn=0105-4538&rft.eissn=1398-9995&rft.volume=73&rft.issue=7&rft.spage=1393&rft.epage=1414&rft_id=info:doi/10.1111%2Fall.13397&rft.externalDBID=10.1111%252Fall.13397&rft.externalDocID=ALL13397 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0105-4538&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0105-4538&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0105-4538&client=summon |